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Kaposi’s sarcoma-associated herpesvirus (KSHV), is the most recently identified human 
herpesvirus and causes a variety of human malignancies. KSHV is etiologically associated with 
Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease 
(MCD). MicroRNAs (miRNAs) are small non-coding RNA molecules that play important post-
transcriptional regulatory roles in gene expression and can greatly influence virus-host cell 
interactions. KSHV is one of a few examples of viruses that encode their own miRNAs. KSHV 
encodes 12 pre-miRNAs which are processed to yield 25 mature miRNAs. To date, extensive 
work has been conducted on the expression and roles of cellular and KSHV-encoded miRNAs 
during virus latency, replication, and angiogenesis. However, little is currently known about the 
roles of microRNAs (miRNAs) in KSHV entry. In the following studies, we investigated the 
induction of cellular miRNA expression in response to initial stages of KSHV infection and their 
roles in virus entry. We employed deep sequencing to analyze miRNA expression in KSHV-
infected BJAB cells at 15min post infection (PI) and compared this to uninfected BJAB cells. 
The expression profile of cellular miRNAs was significantly altered in response to KSHV entry. 
Interestingly, expression of these KSHV-induced miRNAs noted during early stages of infection 
does not require virus replication, as UV-inactivated KSHV could induce the expression of 
cellular miRNAs to comparable levels as live wild-type KSHV. A synthetic mimic for miR-36, a 
novel cellular miRNA expressed in response to KSHV infection, was able to significantly inhibit 
virus entry by targeting the expression of interferon induced transmembrane protein 1 (IFITM1). 
The effect of miR-36 on KSHV infection of cells was at a post-binding stage of virus entry. 
Similarly, miR-36 mimic inhibits infection of closely related DNA viruses: Epstein-Barr virus 
(EBV), and herpes simplexvirus-2 (HSV-2). IFITM1 was observed to have a crucial role in the in 
vitro and in vivo infection of -herpesviruses. IFITM1-specific siRNA inhibits -herpesviruses 
infection in BJAB cells and BALB/c mice. Taken together, our studies provide new insights and 
appreciation for the role of the host cellular miRNAs to inhibit internalization of KSHV which may 
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CHAPTER 1: REVIEW OF LITERATURE 
 
Kaposi’s Sarcoma-Associated Herpesvirus 
Kaposi’s sarcoma-associated herpesvirus (KSHV) also known as human herpesvirus 8 (HHV-8) 
is an enveloped double-stranded DNA virus originally discovered by Chang and Moore at 
Columbia University in Kaposi’s Sarcoma (KS) tissues that were taken from acquired 
immunodeficiency syndrome (AIDS) patients (Bechtel et al., 2005; Chang et al., 1994; Jenner 
and Boshoff, 2002).  
KSHV belongs to Gammaherpesvirinae, a sub-family of the Herpesviridae family, and 
the genus rhadinovirus which is also known as Rhadinoviridae or gamma-2 herpesviruses 
(Taylor and Blackbourn, 2011; West and Damania, 2010; Zhu et al., 1999). KSHV is closely 
related to the primate gamma-2 herpesvirus, herpesvirus saimiri (HVS) and the human gamma-
1 herpesvirus, Epstein-Barr virus (EBV; HHV-4) (Taylor and Blackbourn, 2011; Westmoreland 
and Mansfield, 2008). KSHV consist of ∼165kb dsDNA genome and encodes for more than 90 
ORFs as well as 25 microRNAs (miRNAs) (Arias et al., 2014; Bai et al., 2014). The majority of 
KSHV ORFs are conserved herpesvirus genes expressed by many other members of the family 
(Dourmishev et al., 2003). Additionally, the KSHV genome has its unique ORFs which are 
known as K genes and are specific to KSHV (Bai et al., 2014; Sharma-Walia et al., 2006). Both 
KSHV and EBV are oncoviruses, distinguished by their ability to establish a lifelong persistent 
infection in lymphocytes.  
Owing to the absence of an appropriate experimental model for human -herpesviruses, 
in vivo studies on KSHV and EBV are limited (Cho et al., 2013). The murine gammaherpesvirus 
68 (MHV-68), a member of the subfamily of Gammaherpesvirinae from wild rodents, has been 
developed as an experimental model for these studies (Simas and Efstathiou, 1998). Similar to 
KSHV and EBV, MHV-68 has genetic similarity and exhibits two distinct phases of life cycle 
(latent and lytic replication) (Flano et al., 2000). Thus, MHV-68 is regarded as a substitute for 
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the human -herpesvirus and has been widely used for in vitro and in vivo studies on KSHV and 
EBV (Cipkova-Jarcuskova et al., 2013; Wu et al., 2012). Studies described in Chapter 4 use 
MHV-68 as a model virus to understand the biology of KSHV entry. 
KSHV is an oncogenic virus, able to induce cellular transformation (Ganem, 2010; Jones 
et al., 2012). In vitro and in vivo studies have demonstrated that KSHV has a broad tropism and 
is able to infect a variety of cell types (Hertel, 2011). In vivo, KSHV can infect a variety of cell 
lineages including macrophages, keratinocytes, endothelial cells, and B-Cells, serving as the 
main reservoir (Ganem, 1998; Renwick et al., 2002). In vitro, KSHV can establish infections in a 
much broader range of cells, including human B cells, endothelial cells, epithelial cells, 
fibroblasts, mesenchymal stem cells, dendritic cells, and macrophages (Mesri et al., 1996; 
Rappocciolo et al., 2006; Wu et al., 2006b). 
 
KSHV pathogenesis: Associated-diseases, epidemiology, and treatment 
Studies strongly implicate an etiological association of KSHV primarily with KS, and also with 
two other B cell malignancies: primary effusion lymphoma (PEL) and KSHV-associated 
Castleman Disease (KSHV-MCD) (Neipel and Fleckenstein, 1999; Sharp and Boshoff, 2000).  
KSHV infection affects a wide range of the population with different geographical 
distributions; however, the prevalence of infection varies between geographical locations 
(Whitby et al., 1998). Sub-Saharan Africa has the greatest percentage of KSHV infection 
(seropositivity rates >50%), where KSHV transmission is linked to horizontal transmission & 
intrafamilial/community spread via saliva. Such transmission modes have led KS to become the 
most prevalent cancer among men in Africa (Cao et al., 2014; Dedicoat et al., 2004; Dukers and 
Rezza, 2003; Mbulaiteye et al., 2005; Mbulaiteye et al., 2004). Mediterranean, Middle Eastern, 
and Caribbean countries have intermediate prevalence (seropositivity 20-30%), while KSHV 
infection is less common in Europe, Asia, and the United States (seropositivity <9%) (Dukers 
and Rezza, 2003; Uldrick and Whitby, 2011). 
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Treatment of KSHV-associated diseases is not based on standard guidelines, instead, 
the therapy depends on disease context such as the distribution of the lesions, variant, and 
immune competence in cases of KS (Fatahzadeh, 2012). Therapeutic options include surgical 
excision, chemotherapy, radiotherapy, antiviral therapy, antibodies specific to cytokines 
receptors, or elimination of immunosuppressive therapy in case of transplant-associated KS 
(Hengge et al., 2002; Schwartz, 2004; Szajerka and Jablecki, 2007). Since the advent of the 
highly active antiretroviral therapy (HAART), there has been a sharp decline in the incidence of 
KS in AIDS patients (Franceschi et al., 2010; Gabarre and Bossi, 2003; Gantt et al., 2014). 
Other drugs that are being used to treat KSHV-associated pathogenesis are as follows: 
ganciclovir (GCV), valganciclovir for KS, (Murphy et al., 2017; Schwartz, 2004); foscarnet 
cidofovir, bortezomib, bleomycin for PEL (Dittmer et al., 2012; Lim et al., 2005; Murphy et al., 
2017); and rituximab, siltuximab, tocilizumab for KSHV-MCD (Murphy et al., 2017; Song et al., 
2010; Williams, 2013). 
 
KS: Disease forms and geographic variation 
KS is a multifocal malignancy originally described by Hungarian dermatologist Moritz Kaposi in 
1872 (Stanescu et al., 2007). KS is the most prevalent cancer in HIV-infected patients and 
mainly affecting endothelial cells and manifested as skin lesions (Hussein et al., 2015; Stanescu 
et al., 2007). KS is characterized by three histological features: angiogenesis, inflammation, and 
proliferation (Ensoli et al., 2001). KSHV DNA has been shown to be present in all four forms of 
KS: classical KS (CKS), epidemic KS (AIDS-KS), endemic-KS (EKS), and transplantation-
associated KS (TKS) (Ablashi et al., 2002; Cai et al., 2010b; Ganem, 2010; Pugalagiri et al., 
2013). 
There are variations in the incidence of KS among different populations which in part has 
been attributed to the availability of HAART (Uldrick and Whitby, 2011). In developed countries 
such as the United States, KSHV infection and KS is dramatically decreased because of the 
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availability of HAART. On the other hand, KS is the most common cancer in African countries 
where access to HAART is still limited (Coen et al., 2014; Engels et al., 2008; Gabarre and 
Bossi, 2003).  
 
Virus entry: KSHV utilizes distinct receptors to successfully infect target cells 
KSHV infects target cells in sequential steps (Akula et al., 2003; Kaleeba and Berger, 2006). 
Initially, the virus attaches to the host cell surface molecule, heparan sulfate (HS) (Bryan et al., 
2005; Spear and Longnecker, 2003). Attachment of KSHV to target cells is critical for a 
successful virus infection as it allows envelope associated proteins to make meaningful 
interactions with other cell surface receptor molecules which trigger the actual entry of the virus. 
The internalization of the virus is either by fusion or receptor-mediated endocytosis (Spear and 
Longnecker, 2003).  
KSHV infects cells by different entry mechanisms in a cell type-dependent manner. 
Clathrin-mediated endocytosis seems to be one of the common mechanisms that KSHV utilizes 
to enter cells (Akula et al., 2003; Greene et al., 2007; Walker et al., 2016). KSHV utilizes 
different cell surface receptor molecules including Ephrin Receptor Tyrosine Kinase A2 
(EphA2), dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN), and different 
combinations of integrins such as α3β1, αVβ3, αVβ5, and α9β1 (Chakraborty et al., 2012; 
Chandran, 2010; Hensler et al., 2014; Hussein et al., 2015). These cell surface molecules are 
usually referred to as the entry receptors. Numerous studies have deemed these receptor 
molecules, particularly integrins to be valuable for KSHV infection of cells (Akula et al., 2002; 
Hensler et al., 2014; Rappocciolo et al., 2008). 
 
KSHV has a biphasic life cycle 
The KSHV life cycle is biphasic comprising two sequential phases of replication: latent and lytic 
(Ohsaki and Ueda, 2012). Each phase of KSHV replication is characterized by its unique gene 
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expression profile (Uppal et al., 2015). Shortly after KSHV infection, the virus replication 
switches to the latent phase with only a small percentage (<3%) of infected cells supporting lytic 
replication (Steitz et al., 2011). A dynamic balance between latent and lytic phases of KSHV 
replication is critical to a successful virus infection, establishment of latency, and tumorigenesis 
(Frappier, 2015; Kang et al., 2011a).  
The KSHV latent phase of replication is characterized by a persistent virus infection with 
a restricted expression of viral genes. The key role of the latent phase is to keep the virus 
dormant to evade the immune system, yet maintaining replication of the viral genome (White et 
al., 2012; Zhong et al., 1996). The few KSHV genes that are expressed during the latent phase 
are latency-associated nuclear antigen (LANA), vCyclin, vFLIP, and vIL-6. These genes are 
oncogenes and essential to maintaining the viral episome, promoting cell survival, and inhibiting 
apoptosis; all of which are a necessity to KSHV-induced pathogenesis (Cavallin et al., 2014; 
Mesri et al., 2014; Zhi et al., 2015). 
The molecular mechanisms by which KSHV reactivates from the latent phase and enters 
lytic replication are largely un-known (Traylen et al., 2011). However, a crucial role has been 
described for mitogen-activated protein kinase (MAPK) signaling in KSHV reactivation (Cohen 
et al., 2006; Ford et al., 2006). During the Lytic phase the virus actively replicates with full viral 
gene expression and production of progeny virions (Toth et al., 2013). Once KSHV is 
reactivated, expression of lytic genes occurs in a sequential manner. Lytic genes can be divided 
into three groups: immediate early (IE), early (E), and late (L) genes (Uppal et al., 2014). 
Expression of IE genes occur immediately after reactivation and mainly encode transcription 
factors that are essential for the expression of viral and cellular genes. E genes encode for 
proteins that are required for viral DNA replication (viral polymerases, helicase, and primase) 
(Curreli et al., 2002). L genes encode for viral structural proteins and are expressed at the end 
of lytic replication. The final steps in the lytic phase are virus assembly and the release of 
mature virions (Chang and Kung, 2014). 
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KSHV gene regulation is critical to virus entry 
Viruses hijack preexisting host cell signaling pathways to infect target cells and to generate a 
cellular state that is more receptive to virus infection and replication. One of the best examples 
is KSHV, which is known to activate many cell signaling pathways (Nemerow and Cheresh, 
2002). Activation of these signaling pathways enables KSHV to reprogram host-cells to be 
susceptible to virus infection and to regulate cellular genes important to virus entry, escaping 
from the endosome, and trafficking inside the cytoplasm to reach the nuclear pore. KSHV 
regulates many cellular genes including vascular endothelial growth factor receptor 3 (VEGFR-
3), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), and Rac1 (Kumar and 
Chandran, 2016). These genes are essential to cell survival, proliferation, migration, 
angiogenesis, and contribute to KSHV-associated cellular transformation (Direkze and Laman, 
2004; Hong et al., 2004; Hussein et al., 2016; Wang et al., 2004)  
KSHV regulation of cellular genes occurs as early as 5min post infection of cells (Akula 
et al., 2003). The initial trigger to regulate cellular genes is due to the interactions of envelope-
associated glycoproteins with cell surface receptors (Akula et al., 2002; Naranatt et al., 2003; 
Sharma-Walia et al., 2005; Sharp et al., 2002). KSHV-regulated genes have been shown to be 
critical to virus entry, infection, and virus-associated diseases (Chandrasekharan et al., 2016; 
Direkze and Laman, 2004; Emuss et al., 2009; Engels et al., 2008; Giffin et al., 2015) 
Interactions with a variety of cell surface molecules allow KSHV to phosphorylate and 
activate focal adhesion kinase (FAK). Phosphorylation of FAK leads to activation of several 
focal adhesion-associated signaling molecules, including tyrosine kinase Src, 
phosphatidylinositol-3 kinase (PI3K), Rho GTPases (RhoA, Rac, and Cdc42), Dia2, and other 
effector molecules, such as AKT, ezrin, protein kinase C (PKC), MAPK, NF-kB, and p38MAPK 
which are a necessity for the internalization of virus (Akula et al., 2002; Hussein et al., 2015; 
Pan et al., 2006; Sharma-Walia et al., 2005; Xie et al., 2005). KSHV-activation of Src results in 
the induction of hypoxia-induced factors (HIFs) which in itself is important for KSHV-mediated 
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induction of VEGFR-1 (Carroll et al., 2006). KSHV regulation of the above cellular genes is 
critical to virus entry, infection and virus-associated diseases. The virus activates these genes at 
the early stage of infection to program host-cells to be more susceptible to virus entry and 
infection (Chandrasekharan et al., 2016; Direkze and Laman, 2004; Emuss et al., 2009; Engels 
et al., 2008; Giffin et al., 2015). The focus of this dissertation is on understanding the biology of 
KSHV entry. 
 
Interferon-induced transmembrane proteins 1 
Human interferon-inducible transmembrane 1 (hIFITM1) is a member of interferon-induced 
protein family including IFITM1, IFITM2, IFITM3, IFITM5, and IFITM10. Human IFITMs genes 
are located on chromosome 11 and are highly inducible by type I and II interferons (IFNs) 
(Friedman et al., 1984; Hickford et al., 2012; Reid et al., 1989). 
As with other members of the IFITMs family, IFITM1 has two transmembrane domains 
(TM1 and TM2) which are separated by a highly conserved intracellular loop (Perreira et al., 
2013). IFITM1 is expressed on the surface of many tissues and cell types (Lewin et al., 1991; Li 
et al., 2017; Tanaka et al., 2005). Such ubiquitously expressed IFITM1 modulates several 
cellular functions including immunological responses, proliferation, adhesion, germ cell 
maturation, and development (Hickford et al., 2012; Lewin et al., 1991). IFITM1 is induced by 
interferons and has been shown to be critical for the anti-viral responses (Brass et al., 2009; 
Deblandre et al., 1995; Evans et al., 1990; Smith et al., 2006). 
 
IFITM1 and virus entry 
Recent reports demonstrated that IFITM1 plays a significant role during entry of many viruses 
including influenza A H1N1 Virus, West Nile Virus and Dengue Virus, HIV, HCV, HSV2, EBV, 
and KSHV (Brass et al., 2009; Hussein and Akula, 2017a; Narayana et al., 2015; Yu et al., 
2015b). Based on IFITMs topologies, several mechanisms have been proposed to explain their 
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role(s) in virus entry. However, the exact molecular mechanisms by which IFITMs inhibit or 
enhance virus entry remains to be determined. These proteins have been shown to inhibit virus 
binding to corresponding cellular receptors, blocking virus escape from endosomes, and acting 
as pattern recognizing receptors that activate downstream cellular signal pathways (Brass et al., 
2009). IFITMs inhibit fusion between viral and endosomal membranes by blocking the creation 
of hemifusion, reducing membrane fluidity, and disrupting intracellular cholesterol homeostasis 
(Amini-Bavil-Olyaee et al., 2013; Li et al., 2013a).  
IFITM1 has been shown to inhibit syncytia formation by viral proteins. Likewise, IFITM2 
and IFITM3 inhibit fusion of viral glycoproteins with cell membranes in a cell type-specific 
manner. Interestingly, inhibition of virus entry by IFITMs has been shown to be specific to viral 
glycoproteins (Brass et al., 2009). On the other hand, over-expression of IFITM1 partially 
inhibited the infection of vesicular stomatitis virus but had no significant effect on the infection of 
influenza virus (Alber and Staeheli, 1996). Similarly, IFITM1 has no inhibitory effect on the 
infection of Rift Valley fever virus which has been shown to be significantly inhibited by IFITM2 
and IFITM3. The authors of this study reported that a large fraction of IFITM1 proteins localized 
in vesicular compartments differ from those occupied by IFITM2 and IFITM3 (Mudhasani et al., 
2013). Likewise, Warren et al reported that IFITM1, IFITM2, and IFITM3 had no inhibitory effect 
on infection of human papillomavirus 16 (HPV16), human cytomegalovirus (HCMV) and 
adenovirus type 5 (Ad5). They determined IFITM1 and IFITM3 to modestly enhance HPV16 
infection of many cell types (Warren et al., 2014). In accordance with the above results, Zhao et 
al., have shown type I IFN-α, IFN-γ, and type II IFN-λ to significantly promote infection of the 
human coronavirus, HCoV-OC43 by the induction of IFITM proteins. The authors reported that 
the IFITM2 or IFITM3 act as entry factors facilitating HCoV-OC43 infection of Huh7.5 cells 
(Zhao et al., 2014). The results suggest that roles of IFITMs during virus infection could be virus 
and/or cell-type specific. 
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The above variations in the mode of action between IFITM1, IFITM2 and IFITM3 during 
virus infection could be explained by the fact that IFITM1 primarily localized to the plasma 
membranes and early endosomes, while IFITM2 and IFITM3 were mainly expressed on late 
endosomes, lysosomes, and autolysosomes (Feeley et al., 2011; Huang et al., 2011; Perreira et 
al., 2013; Yount et al., 2010). Chapter 3 of this work describes a crucial role for IFITM1 in the 
biology of KSHV entry. 
 
miRNAs: Biogenesis and mechanism of action 
MicroRNAs (miRNAs) are a class of highly conserved small non-coding RNAs of ~ 22 
nucleotides in length. The first discovered miRNA is lin-4 which was identified by Ambros and 
Ruvkun labs in 1993 from Caenorhabditis elegans (C. elegans) (Lee et al., 1993; Wightman et 
al., 1993) . miRNA lin-4 was described to regulate lin-14 mRNA translation during the early 
larval stage of the worm (Lee et al., 1993; Rougvie, 2001; Wightman et al., 1993). Subsequent 
work revealed that the miRNAs act as post-transcriptional regulators of gene expression in 
many organisms (Chen, 2005; Cock et al., 2010; Cuperus et al., 2011; Ninova et al., 2016; 
Wienholds and Plasterk, 2005). The current release of the miRBase database (miRBase 
release 21) contains 28645 microRNA loci from 223 species which produce 35828 mature 
microRNAs (Kozomara and Griffiths-Jones, 2014; Van Peer et al., 2014). The miRBase 
database is gradually increasing with over 2000 human miRNA sequences currently deposited 
in the most recent release of the mirBAse database (miRBAse 21) (Hammond, 2015; Kozomara 
and Griffiths-Jones, 2014). 
Transcription of miRNA genes is mainly mediated by RNA Polymerase II and to a lesser 
extent by RNA polymerase III (Ha and Kim, 2014; Ketting, 2010; Lee et al., 2004; Macfarlane 
and Murphy, 2010). In general, miRNA genes are transcribed as several kilobase long 
transcripts called primary miRNAs (Pri-miRNAs) (Cai et al., 2004). Pri-miRNAs are processed in 
the nucleus to ~ 60-70- nucleotide long miRNAs precursors (Pre-miRNAs) by the 
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microprocessor, a complex of proteins composed of the RNAs III enzyme Drosha and its 
binding protein DGCR8 (Han et al., 2006). Subsequently, Pre-miRNAs are transported by 
Exportin-5 from the nucleus to the cytoplasm where they are trimmed by Dicer, another RNAs III 
enzyme (Chendrimada et al., 2005; Okada et al., 2009). Dicer products are 19-25 nt long RNA 
duplexes with a 3’ 2-nt overhang. These miRNA duplexes are then loaded into the RNA-induced 
silencing complex (RISC) which includes the Ago proteins. The majority of miRNAs are 
produced by the canonical method described above, however,  there are many alternative 
pathways for miRNAs biogenesis (Havens et al., 2012; Sibley et al., 2012; Yang and Lai, 2011). 
These include miRNAs that are generated in a microprocessor, or Dicer independent-ways (Coll 
et al., 2010; Eckenfelder et al., 2017; Herrera-Carrillo and Berkhout, 2017; Shapiro et al., 2010). 
Once loaded to RISC, one strand of the miRNAs duplexes called the passenger strand 
gets ejected, while the other strand referred to as the guide strand directs the Ago proteins to 
the respective mRNA target(s) (Hutvagner and Zamore, 2002a, b; Khvorova et al., 2003). The 
seed region, positions 2-8 from the 5’ end of the guide strand is critical for miRNA binding to its 
target (Bartel, 2009). Mutations in the seed region of miRNAs have been shown to strongly 
impact the ability of miRNA to bind its targets (Kertesz et al., 2007; Mencia et al., 2009). The 
majority of miRNAs bind to 3’-UTR of mRNA targets, however, miRNAs can also bind to the 
CDS and 5’-UTR of their targets (Gu et al., 2009). 
The fate of miRNA targets depend on the level of complementarity between the miRNA 
and mRNA target. Low complementarity induces translational silencing, while high 
complementarity triggers degradation of mRNA (Bartel, 2004; Lewis et al., 2005). In both cases, 
miRNAs lead to a decrease in expression of respective proteins. A single miRNA can regulate 
hundreds of targets in an efficient way, conversely, multiple miRNAs can cooperatively regulate 
a single target (Zhou et al., 2013). Besides their role in the suppression of gene expression, 
miRNAs can also activate gene expression. The liver-specific miRNA, miR-122, has been 
shown to significantly enhance hepatitis C virus (HCV) infection and gene expression via 
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binding to the 5’-UTR of the viral RNA and protecting it from exonuclease activity (Li et al., 
2013b). Similarly, miR-10a and miR-369-3p bind and activate expression of the ribosomal 
protein and TNF-α mRNAs respectively (Orom et al., 2008; Vasudevan and Steitz, 2007).  
The accumulated evidence implicate miRNAs as gene regulators for about 60% of 
protein-coding genes. miRNA regulations have been shown to be critical for many vital 
mechanisms including maintenance of homeostasis, disease pathogenesis, and immunological 
responses to infection (Eulalio et al., 2012).  
 
KSHV encodes miRNAs 
Viruses have no miRNA processing machinery, yet many viruses encode miRNAs in their 
genomes including viruses from herpesviruses, adenovirus, polyomavirus, and retrovirus 
families (Cullen, 2011; Gourzones et al., 2012; Kincaid and Sullivan, 2012; Lieber and Haas, 
2011; Nourse et al., 2012; Zhang et al., 2014). The majority of herpesviruses that infect humans 
encode their own miRNAs including viruses from Table 1 (Kincaid and Sullivan, 2012; Pfeffer et 
al., 2005; Wong et al., 2012). 
One of the best examples of viruses that encode their own miRNA is KSHV. KSHV-
encoded miRNAs have been described independently by several groups as early as 2005 (Cai 
et al., 2005; Pfeffer et al., 2005; Samols et al., 2005). Subsequent work revealed that the KSHV 
genome encodes 13 pre-miRNAs which are processed by cellular machinery to yield 25 mature 
miRNAs (Table 1) (Gottwein et al., 2011; Guo et al., 2017; Qin et al., 2017b). Names, 
sequences, and locations of  KSHV encoded miRNAs and their precursors are provided in 
Table 2 (Lin et al., 2010). Interestingly, KSHV-miRNAs have been shown to dominate the small 
RNA sequencing data generated from KSHV infected B-cell line BC-3 (Umbach and Cullen, 
2010).  
Tha majority of known KSHV-miRNAs are located in the latent locus and expressed 
during the latent phase of virus infection (Cai et al., 2005; Samols et al., 2005). KSHV-miR-K12-
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10 and KSHV-miR-K12-12 are expressed more during the lytic phase and located within ORF 
and 3′UTR of kaposin, respectively (Lin et al., 2010). The rest of KSHV-miRNAs are expressed 
strictly during the latent phase from a ~ 4-kb noncoding sequence located between the kaposin 
and ORF71 (v-FLIP) genes (Cai et al., 2005; Gottwein et al., 2006; Qin et al., 2017b). 
 
KSHV-encoded miRNAs promote virus latency and pathogenesis 
Upon the discovery that KSHV encodes a considerable number of miRNAs, the initial focus has 
been to study the contributions of these miRNAs to KSHV infection and pathogenesis (Samols 
et al., 2007). Subsequent work revealed that KSHV-encoded miRNAs are able to regulate the 
expression of both viral and cellular genes that are essential to virus infection and the 
associated diseases (Dolken et al., 2010; Guo et al., 2017; Happel et al., 2016; Li et al., 2016a; 
Qin et al., 2017b; Samols et al., 2007). 
KSHV-encoded miRNAs are expressed abundantly during the latent phase of virus 
infection. As latency is the default phase of KSHV infection, several studies have focussed their 
interests in determining the functions of these miRNAs in supporting viral latency (Chen et al., 
2013; Gottwein, 2012; Lei et al., 2010). In 2009, Bellare and Ganem reported that the KSHV-
miR-K12-9-5p inhibits virus reactivation by targeting the expression of replication and 
transcription activator (RTA), a KSHV immediate early gene, which is crucial to viral reactivation 
from latency (Bellare and Ganem, 2009). Moreover, elevated expression of RTA has been 
reported in cells infected with a mutant KSHV lacking 14 of the virus-encoded miRNAs (Lei et 
al., 2010). Similar studies conducted by Lu et al., using a mutant virus indicated that the KSHV 
miRNAs maintain virus latency via targeting many genes including RTA and cellular 
retinoblastoma (Rb)-like protein 2 (Rbl2) gene which regulate epigenetic reprogramming (Lu et 
al., 2010). 
KSHV miRNAs inhibit apoptosis of latently infected cells via targeting of apoptotic genes 
(Cai et al., 2005; Guo et al., 2017; Qin et al., 2017b). Suffert et al., reported that the HEK293 
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epithelial cells and DG75 cells expressing KSHV miRNAs were protected from apoptosis 
(Suffert et al., 2011). Subsequently, they determined KSHV miRNAs, miR-K12-1, -3 and -4-3p, 
to target Casp3 and block apoptosis. Inhibition of these miRNAs with specific oligonucleotides 
directed to the seed regions enhances apoptosis of KSHV-infected cells (Suffert et al., 2011). 
Moreover, KSHV miRNAs modulate angiogenesis, signaling pathways, cell cycle, cell migration, 
and adhesion which are critical to KSHV dissemination and pathogenesis (Gallaher et al., 2013; 
Li et al., 2016a; Li et al., 2016b; Liu et al., 2017b; Samols et al., 2007). By this way, KSHV 
miRNAs promote tumorigenesis. 
KSHV miRNAs also enhance immune evasion and viral pathogenesis by regulating host 
immune responses. Several groups independently reported that the KSHV miRNAs impact the 
functions of immune effector cells and thus alter the secretion pattern of many cytokines 
including IL-8, IL-10, and IL-6 (Boss and Renne, 2010; Gallaher et al., 2013; Nachmani et al., 
2009; Qin et al., 2010). The aberrent expression of these cytokines is a necessity to KSHV-
associated diseases (Polizzotto et al., 2012; Tamburro et al., 2012). 
 
Roles of cellular miRNAs in KSHV entry, replication, and pathogenesis 
Beside encoding its own miRNAs, KSHV infection of the cell has been shown to significantly 
alter the expression of many cellular miRNAs. These miRNAs, in turn, regulate KSHV entry, 
replication, pathogenesis, and immune evasion (Choi et al., 2015; Qin et al., 2014). A miRNA 
microarray profiling of six paired KS and matched adjacent healthy tissues revealed that 170 
cellular miRNAs that were differentially expressed in KS tissues compared to healthy tissues 
(Wu et al., 2015). A large number (n=101) of these miRNAs including miR-125b-1-3p and miR-
1183 were downregulated, while the rest (69 miRNAs) were upregulated and that included miR-
126-3p, miR-199a-3p, and miR-16-5p (Wu et al., 2015). In a similar study, Catrina Ene et al., 
reported 185 differentially expressed miRNAs (76 were upregulated and 109 were 
downregulated) in KS tissues versus normal skin. The most significantly downregulated miRNAs 
14 
 
in this study were cellular miRNAs: miR-99a, miR-200 family, miR-199b-5p, miR-100, and miR-
335 (Catrina Ene et al., 2014). Similar studies reporting profiling of cellular miRNAs in KSHV-
associated diseases has been conducted by several independent groups (Chugh et al., 2013; 
Lagos et al., 2010; O'Hara et al., 2008; O'Hara et al., 2009).  
 Similar to KSHV-encoded miRNAs, cellular miRNAs can also promote viral latency by 
inhibiting reactivation (Frappier, 2015; Yan et al., 2016). Many of the cellular miRNAs like miR-
498, miR-320d, miR-557, miR-766, miR-1227, miR-1258, and miR-1301 have been shown to 
target mRNA of viral lytic activator RTA (Murphy et al., 2008; Yan et al., 2013; Yan et al., 2014). 
KSHV-induced cellular miRNAs are also involved in KSHV-induced angiogenesis. KSHV-K15, a 
viral oncoprotein has been shown to induce cell migration and angiogenesis via upregulation of 
cellular miR-21 and miR-31 (Tsai et al., 2009). Similarly, downregulation of miR-221/miR-222 
cluster by KSHV infection has been reported to enhance the migration pattern of endothelial 
cells (Wu et al., 2011). In a way, KSHV-induced cellular miRNAs work in unision with the KSHV 
encoded miRNAs to promote latency and tumorigenesis. 
The majority of the above work has been dedicated to studying the induction and 
contributions of miRNAs after the virus has succesfully established latency. For the first time, 
studies from our lab explored the ability of KSHV to alter expression of cellular miRNAs during 
early stages of infection; as early as 15min PI (Hussein and Akula, 2017b). We identified 
several cellular novel miRNAs which are upregulated during the initial stages of KSHV entry 
(Chapter 2). One of these miRNAs, miR-36, was able to inhibit the entry of not only KSHV but 
also related viruses, EBV and HSV-2 (Hussein and Akula, 2017a). miR-36 inhibits virus entry 
via targeting the expression of IFITM1, that functions as non-specific antiviral protein. 
 
Cellular miRNAs mediate immunity against viral pathogens 
Several viruses have been shown to significantly alter the expression of cellular miRNAs in 
infected cells (Bruscella et al., 2017; Skalsky and Cullen, 2010). This could be in part due to the 
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mechanism by which cells mount antiviral responses, or viral factors that inhibit cellular 
responses and change the intracellular milieu to support virus replication and infection 
(Bruscella et al., 2017; Cullen, 2013; Gottwein, 2013; Swaminathan et al., 2013; Trobaugh et al., 
2014).  
In general, the contributions of small RNAs to the antiviral response in chordates 
remains elusive compared to plants, arthropods, and nematodes (Cullen, 2010; tenOever, 
2013). However, accumulating evidence indicates a crucial role for cellular miRNAs in antiviral 
immunity (Gantier et al., 2007; Skalsky and Cullen, 2010). Levels of miRNAs have been shown 
to correlate with the expression of interferons during virus infection (Lindsay, 2008; Pedersen et 
al., 2007). Pederson et al., have shown that Interferon β induced by hepatitis C virus (HCV) 
rapidly modulates the expression of numerous cellular miRNAs. In turn, several of these 
miRNAs have been shown to target the HCV genome (Pedersen et al., 2007). Similarly, Dicer-
deficient mice are more susceptible to infection with cytomegalovirus and vesicular stomatitis 
virus (VSV) (Ostermann et al., 2012; Otsuka et al., 2007). These studies demonstrate that the 
miRNAs are critical to mounting rapid antiviral responses such as interferon and interferon-
inducing genes. 
 Cellular miRNAs have been shown to directly target the genome and transcripts of many 
viruses including HIV, HCV, HBV, VSV, and KSHV viruses (Chen et al., 2011; Forster et al., 
2015; Jopling et al., 2005; Nathans et al., 2009; Skalsky and Cullen, 2010). Kang et al., reported 
cellular miR-1293 to target KSHV IL-6, an essential protein for KSHV-mediated diseases, 
especially in the inflammatory cytokine syndrome associated with KSHV infection in AIDS 
patients (Kang et al., 2011b). Interestingly, KSHV has also evolved mechanisms to use cellular 
miRNAs to evade antiviral innate immune responses. miR-123, a cellular miRNA induced by 
KSHV in endothelial cells target the p300 transcriptional co-activator which negatively regulate 
the expression of interferon-stimulated genes and enhance virus replication (Lagos et al., 2010; 
Qin et al., 2014). 
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Studies from our recently concluded work described a crucial role for the KSHV-induced 
cellular miR-36 to inhibit virus infection in both B and endothelial cells which are the main 
targets of KSHV infection in vivo (Hussein and Akula, 2017a). Interestingly, miR-36 was able to 
inhibit infection of not only KSHV, but also EBV, and HSV-2 viruses. We were able to detect up-
regulation of miR-36 as early as 15 minutes post-KSHV infection (Hussein and Akula, 2017b). 
Subsequently, we found that miR-36 inhibits virus infection by targeting the expression of 
IFITM1 protein (Hussein and Akula, 2017a). Chapters 2, 3, and 4 are aimed at describing our 
findings on miR-36, and IFITM1 on KSHV infection, in vitro and in vivo. 
 
Targeting miRNAs for anti-viral and anti-cancer therapies 
Cellular and viral miRNAs are attractive targets to design pathogen-specific antiviral therapies 
(Bofill-De Ros et al., 2017; Bruscella et al., 2017; Skalsky and Cullen, 2010). miRNA-based 
therapies could be formulated in two different forms: mimicking miRNA functions using miRNA-
specific oligonucleotide mimics or silencing miRNA functions by miRNA-specific antisense 
oligonucleotide inhibitors (anti-miRNA) (Baigude and Rana, 2014; Reid et al., 2016; Tang and 
Tang, 2013). 
There are several miRNA-based therapies currently being tested in human clinical trials 
(Christopher et al., 2016; Titze-de-Almeida et al., 2017). One of the most common examples of 
miRNA-based antiviral therapy is miR-122 antisense oligonucleotide inhibitor (miravirsen, 
Santaris Pharma, Hørsholm, Denmark). Miravirsen has been shown to be promising for 
treatment of HCV infection (de Jong and Jacobson, 2014; Janssen et al., 2013a; Janssen et al., 
2013b). Interestingly, Miravirsen administration to 36 patients with chronic HCV genotype 1 
infection resulted in a reduction of 1.2 to 3.0 log international units (IUs)/mL in HCV RNA levels 
in a dose-dependent manner without induction of virus resistance (Janssen et al., 2013b). In a 
recent and more promising study, Van der Ree et al., reported that the administration of 2mg/kg 
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or 4mg/kg RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated anti-miR-122 
oligonucleotide, induced a significant reduction in HCV RNA levels (van der Ree et al., 2017).  
As discussed above, miRNAs are able to directly target the viral genome, thus 
ubiquitously expressed miRNA can be harnessed to generate safe and effective live-attenuated 
vaccines (tenOever, 2013). Incorporation of tissue-specific miRNA target sequences into 
attenuated vaccines prevent the virus from replicating in this tissue (Drury et al., 2017; 
tenOever, 2013). Insertion of neuronal-specific miR-124 target sites into poliovirus genome 
inhibits the replication of the virus in the central nervous system. The engineered virus strain 
was able to elicit a strong protective immunity without producing neurovirulence in infected 
animals (Barnes et al., 2008). A similar approach has been applied to engineer safe and 
effective live attenuated vaccine strains for West Nile virus, dengue virus, influenza virus, VSV, 
and measles virus (Brostoff et al., 2016; Drury et al., 2017; Heiss et al., 2011; Kelly et al., 2010; 
Leber et al., 2011; Perez et al., 2009). 
Similar to treating viral infections, miRNA-based therapies to treat for many cancers 
including that of lung cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, 
and breast cancer are currently at preclinical and clinical phases of development (Christopher et 
al., 2016; Henry et al., 2011; Ibrahim et al., 2011; Liu et al., 2011; Pecot et al., 2013; Pramanik 
et al., 2011; Trang et al., 2011). miR-221 silencing using chol-anti-miR-221 blocks 
hepatocellular carcinoma and promote mouse survival. Chol-anti-miR-221 was able to inhibit 
tumor cell proliferation and increase the markers of apoptosis and cell-cycle arrest (Park et al., 
2011). Studies described under chapters 2-4, we hope, will yield antiviral therapy to prevent 













Table1. Numbers of Pre-miRNA hairpins and mature miRNAs encoded by human 
herpesviruses. 









α-herpesviruses HSV-1 (Herpes simplex virus 1) 18 27 (Cui et al., 2006; Jurak et al., 
2010) 
HSV-2 (Herpes simplex virus 2) 18 24 (Jurak et al., 2010; Tang et al., 
2009; Umbach et al., 2010) 
β-herpesviruses CMV (cytomegalovirus) 15 26 (Meshesha et al., 2012; Stark et 
al., 2012) 
Human herpesvirus 6B 4 8 (Tuddenham et al., 2012) 
γ-herpesviruse EBV (Epstein Barr virus) 25 44 (Cai et al., 2006; Cosmopoulos 
et al., 2009; Landgraf et al., 
2007; Pfeffer et al., 2004) 
KSHV (Kaposi’s sarcoma-
associated herpesvirus) 
13 25 (Cai et al., 2005; Lin et al., 
2010; Qin et al., 2017b; 
Umbach and Cullen, 2010) 
*Numbers of viral pre-miRNAs and mature RNAs based on the most recent release of miRBase 
(miRBase 21: http://www.mirbase.org/index.shtml ). 
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Table 2. Names and sequences of KSHV-encoded miRNAs and their precursors*. 
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Kaposi’s sarcoma-associated herpesvirus (KSHV) causes a variety of cancers, including 
Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease 
(MCD). Host cellular microRNAs (miRNAs) play important post-transcriptional regulatory roles in 
gene expression and can greatly influence virus-host cell interactions. This study investigated 
cellular miRNA expression profiles operating in response to early stages of KSHV infection of 
human Burkitt lymphoma B cells (BJAB). We employed deep sequencing to analyze miRNA 
expression in KSHV-infected BJAB cells 15min post infection (PI) as compared to the 
uninfected BJAB cells. A total of 32 known miRNAs and 28 novel miRNA candidates were 
differentially expressed in KSHV-infected and uninfected BJAB cells. Interestingly, miRNA 
expression profiles during early stages of viral infection yielded comparable results when UV-
inactivated KSHV was used. The deep sequencing results were further confirmed by performing 
real-time reverse transcription PCR. The predicted target genes regulated by both known and 
novel miRNAs were mainly involved in assisting virus entry, inducing critical cell signaling, 
initiating transcription of immediate early genes, promoting latent infection, and modulating the 
host immune response. For the first time, we provide some insight into the host cellular miRNA 
expression profiles in response to early stages of KSHV infection of human B cells. 
Furthermore, this study offers a valuable basis for further investigation on the roles of cellular 








Kaposi’s sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8) is an 
oncogenic virus classified under the family of herpesviridae (subfamily: γ2-herpesvirinae) 
(Chang et al., 1994). KSHV is among the list of viral pathogens estimated to cause 12-25% of 
human cancers worldwide (La Ferla et al., 2013; Morrison et al., 2015). KSHV primarily causes 
Kaposi’s sarcoma (KS) (Schalling et al., 1995) and is also etiologically associated with other 
lymphoproliferative diseases such as primary effusion lymphoma (PEL) and multricentric 
Castleman disease (MCD) (Hamden et al., 2005; Soulier et al., 1995). Prevalence of KSHV 
infection is directly correlated to KS incidence and varies according to geographic location, 
ethnicity, and distinct behavioral risk factors (Labo et al., 2014). 
The KSHV genome consists of linear double-stranded DNA (dsDNA) and the virus 
displays two modes of replication in the infected cells: latent and lytic replication phase (Ford et 
al., 2006; Lukac et al., 1998). The default pathway of KSHV infection both in vivo and in vitro is 
latent (dormant) infection (Steitz et al., 2011); at any given instance, only a subpopulation (<3%) 
of infected cells display evidence of lytic gene expression (Cai et al., 2010a; Dyson et al., 2008; 
Sun et al., 1999). Establishing latency allows KSHV to evade the host’s immune surveillance, 
maintain persistent life-long infections, and promote tumorigenesis (Yang et al., 2015). Using 
PCR arrays, we identified crucial cellular genes that can reactivate latent KSHV infections 
(Bryan et al., 2006). 
MicroRNAs (miRNAs) are important regulators of gene expression (Trionfini and 
Benigni, 2017) that are short (~22 nucleotides long), endogenous, non-coding RNAs (Krol et al., 
2010; Treiber et al., 2012). The human genome encodes thousands of miRNAs (Kozomara and 
Griffiths-Jones, 2011). KSHV is among the limited number of viruses that encode their own 
miRNAs (Pfeffer et al., 2004). There are several published works that describe virus and cellular 
encoded miRNAs in KSHV pathogenesis (Chen et al., 2016; Krause et al., 2016; Liu et al., 
2017b). However, to date, no publication has profiled the expression of cellular miRNAs during 
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early stages of KSHV infection. KSHV internalization involves well-orchestrated interactions 
between the virus and the host cell at different levels: surface receptor molecules, host defense, 
endocytosis, capsid transport, and finally the replication of the viral genome (Bryan et al., 2005). 
Thus, the present study aimed to investigate cellular miRNA expression profiles operating in 
response to early stages of KSHV infection of cells. The study also aimed to predict target 
genes which might be useful in understanding host cellular mechanism as it pertains to 
promoting or inhibiting virus entry. 
 
MATERIALS AND METHODS 
Cell culture and virus 
Human Burkitt lymphoma B cell line (BJAB) was used in this study. BJAB was propagated in 
phenol red–free RPMI medium (Invitrogen, Carlsbad, CA) containing 10% charcoal-stripped 
fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), L-glutamine, and antibiotics (Akula 
et al., 2005). 
 
KSHV and UV-KSHV 
Wild-type KSHV (Akula et al., 2004) and UV-inactivated KSHV (UV-KSHV) was used in this 
study. Replication-incompetent KSHV was prepared by exposing it for 20min under a UV light 
source (365 nm) (Naranatt et al., 2003). Both KSHV and UV-KSHV were concentrated and 
gradient purified using nycodenz (Sigma) as per standard protocols described earlier (Akula et 
al., 2002). To confirm the successful inactivation of KSHV by exposing it to UV light, we 
performed infection of BJAB cells using 10 MOI of KSHV exposed to normal light while another 
lot of 10 MOI of KSHV that was exposed to UV-light source. After 30 min post infection, cells 
were lysed, RNA extracted, cDNA synthesized, and the expression of ORF50 monitored by 
qRT-PCR using specific primers as per earlier studies (Dyson et al., 2010). Expression of 
ORF50 was used as a scale to measure KSHV infection of cells. ORF50 is expressed 
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immediately upon KSHV infection of cells (Dyson et al., 2010; Krishnan et al., 2004). As 
reported in earlier studies (Walker et al., 2014), the lowest limit of detection in the standard 
samples was 6–60 copies for the ORF50 gene.  
 
KSHV infection of cells and RNA extraction 
BJAB cells were infected with 10 multiplicity of infection (MOI) (Hamden et al., 2004; Walker et 
al., 2014). The cells were left uninfected or infected for 15min prior to washing the cells twice in 
PBS and processed appropriately for RNA extraction. Total RNA was extracted using TRIzol 
(Invitrogen, Carlsbad, CA). The RNA concentration was measured with a NanoDrop ND-2000 
spectrophotometer (Thermo Fisher Scientific< Waltham, MA), and then verified for quality using 
an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only RNA samples with 
integrity number greater than 9 were used in the following steps. 
 
sRNA library construction and sequencing 
The total RNA samples were fractionated by 15% denaturing polyacrylamide gel 
electrophoresis, and then sRNA fragments between 16 and 30nt in length were isolated from 
the gel. The sRNA molecules were ligated to a 5′ adaptor and a 3′ adaptor by T4 RNA ligase 
(Promega, Madison, WI). Subsequently, the adapter-ligated sRNAs were converted to cDNA by 
RT-PCR using Superscript III kit (Invitrogen). The library was enriched by PCR employing 
specific primers and the products were then purified. The PCR products contained within the 
library were assessed by Agilent Bioanalyzer DNA 1000. The miRNA enriched samples were 
extracted from the above constructed sRNA libraries using a 3% Pippin prep (Sage Science) gel 
cassettes. Libraries were sequenced on an Illumina HiSeq 2000 using TruSeq SBS sequencing 
kit ver 3and SCS version 1.4.8 data collection software (Sun et al., 2016). 
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miRNA-seq data analysis 
The miRNA sequence data for each sample was processed and analyzed as per standard 
procedures described earlier (Ning et al., 2014). The analysis was further confirmed by the use 
omiRas, a web server for the annotation, comparison, and visualization of interaction networks 
of non-coding RNAs (Muller et al., 2013). The differential expression of miRNAs was calculated 
on the basis of the difference (cutoff, ±2.0-fold or more) observed between different groups 
(uninfected versus KSHV infected cells 15min post infection). The P value of differentially 
expressed miRNAs was estimated via z score by using a Benjamini-Hochberg FDR corrections 
of 0.05 as described earlier (Klipper-Aurbach et al., 1995). 
 
Real-time qRT-PCR analysis of the expression of miRNAs 
The quality of RNA was tested using a spectrophotometer. Only the RNA samples with 260/280 
ratios of 1.8 to 2.0 were used in the study. Approximately 500ng of RNA was reverse 
transcribed in a 25µl reaction volume using the All-in-oneTM miRNA qRT-PCR detection kit 
(GeneCopoeia, Rockville, MD). Briefly, the cDNA was synthesized in a 25μl reaction mix 
containing 5μl of 5x reaction buffer, 2.5U/μl Poly A Polymerase, 10ng/μl MS2 RNA, and 1µl 
RTase Mix. The reaction was performed at 37°C for 60 min and terminated at 85°C for 5 min. 
cDNA that was produced in the RT reaction was diluted ten-fold and was used as the template 
for the PCR reaction in an Applied Biosystems ViiA 7 Real-Time PCR System (Life 
Technologies, USA). In this system, MS2 RNA was used as an external reference for the quality 
of the extracted miRNAs, and RNU6B was used for normalization. The expression levels of 
miRNAs were measured employing qRT-PCR with the SYBR green detection and specific 





miRNA target prediction 
The target genes for each differentially expressed miRNA were predicted using the miRanda 
(http://www.microrna.org/), MicroRNA Target prediction (miRTar; 
mirtar.mbc.nctu.edu.tw/human/index.php), and DIANA tool (http://diana.imis.athena-
innovation.gr/DianaTools/index.php) algorithms. To further authenticate the biological function of 
the predicted target genes, a Kyoto Encyclopedia of Genes Genomes (KEGG) pathways 
enrichment analysis was performed using the KOBAS 3.0 annotation tool (Wu et al., 2006a). 
 
Real-time qRT-PCR analysis of the expression of putative target genes. The experimental 
approach was done as per earlier protocols (Dyson et al., 2012). The primer sets used to 
monitor expression DLG5 was 5’-CTATGACGCCCTTCGGAAGAG-3’ (sense) and 5’-
TCATGGTGGATCGCCTCAAAC-3’ (antisense). The primers used to monitor expression of 
IRF5, CPLX1, and SPTBN4 is described in earlier studies (Barnes et al., 2001; Kurokawa et al., 
2015; Sanchez-Mut et al., 2013). 
 
Western blotting 
BJAB cells were KSHV infected for 30min. The cells were washed twice in PBS prior to lysing 
them using gold lysis buffer (GLB) (Akula et al., 2004). Equal amounts (25µg) of protein were 
resolved by SDS 12% PAGE, blotted on to a PVDF membrane (EMD Millipore), blocked in 
blocking buffer overnight at 4C, incubated with sheep anti-IRF5 polyclonal antibody (R&D 
systems, Minneapolis, MN), rabbit anti-DLG5 polyclonal antibody (Abcam, Cambridge, MA), 
mouse anti-CPLX1 monoclonal IgG (R&D systems), or goat anti-SPTBN4 polyclonal antibody 
(Abgent, San Diego, CA) for 2h at room temperature followed by incubating with appropriate 
HRP-conjugated antibodies (KPL, Gaithersburg, MD) for 60min at RT, and finally developed 
using chemiluminescent reagent (NEN Life Science, Boston, MA). Membranes were ‘stripped’ 
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Construction and sequencing data analysis of sRNA libraries 
The purpose of this study was to understand the changes in the expression profile of miRNAs 
during early stages of KSHV infection of cells. Accordingly, we used BJAB cells to study such 
changes induced during KSHV infection of cells. Human B cells is one of the major in vivo 
targets of KSHV infection (Myoung and Ganem, 2011; Naranatt et al., 2004) and that is the 
prime reason we chose to work with BJAB cells. To identify miRNA changes in BJAB cells 
infected with KSHV, two small RNA (sRNA) libraries pooled from uninfected and KSHV-infected 
groups were constructed at 15min post infection (PI). We performed high-throughput sRNA 
sequencing using the Illumina platform on sRNA libraries obtained from KSHV-infected BJAB 
cells, and compared the results to those obtained using uninfected cells. As shown in Table 1, a 
total of 17,093,083 and 12,203,413 raw reads were obtained from the uninfected and KSHV-
infected groups, respectively, at 15min PI. After removing low-quality sequences, adapter 
sequences, and sequences smaller than 16nt, 15,296,253 and 12,278,645 clean reads were 
identified in the uninfected and KSHV-infected cells, respectively, at 15min PI. All of the clean 
reads were annotated and classified as miRNA, rRNA, tRNA, piRNA, snoRNA, scRNA, and 
snRNA (Table 2). The majority of the length distribution of the sRNAs were 22–23nt in length 
(Fig 1), which is consistent with the typical size of mature miRNAs (Liu et al., 2015). These 
results indicate that miRNAs have been enriched successively from all the libraries. 
 
Differential expression analysis of known miRNAs 
To identify known miRNAs in BJAB cells, we aligned the sRNAs from our libraries to the known 
mature miRNAs in the Sanger miRBase 21.0 database using BLASTN searches to obtain the 
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miRNA count as well as the base bias at the first position. At 15min PI, approximately 2220 
unique sequences in the uninfected library (Supplementary Table 1) and 2020 unique 
sequences in the KSHV-infected library (Supplementary Table 2) were annotated as sRNA 
candidates. A total of 757 and 672 known miRNA genes were identified in the uninfected 
(Supplementary Table 3) and KSHV-infected (supplementary Table 4) BJAB cell libraries, 
respectively. Using a P-value<0.01 and a │log2 (fold change)│ >2 as the cut-off values, a total 
of 32 known miRNAs were differentially expressed in the two groups, and heat maps showing 
the relative expression of miRNAs in uninfected versus KSHV-infected cells at 15min PI is 
provided in Fig. 2. 
 
Prediction and differential expression of novel miRNAs 
After removing the snRNAs, snoRNAs, rRNAs, and known miRNAs, we aligned the remaining 
unannotated reads against the H. sapiens genome to predict novel miRNAs in the BJAB cells. 
Using miRDeep software, 125 novel miRNAs were predicted at 15min PI of BJAB cells 
(Supplementary Table 5). According to the cut-off values of the differential expression analysis 
discussed previously, 28 miRNAs were differentially expressed during the early stages of KSHV 
infection of cells. A total of fourteen miRNAs were upregulated and fourteen were 
downregulated in KSHV-infected cells (p<0.01) (Fig. 3). The original sequences of the novel 
miRNAs with appropriate IDs and specific primers are provided in the Table 3. 
 
Authentication of differentially expressed miRNAs by qRT-PCR and target prediction 
To validate the sequencing data, we selected five known miRNAs and twenty eight novel 
miRNA candidates for qRT-PCR analysis. All 34 miRNAs showed expression profiles that were 
consistent with the sRNA sequencing data. The expression of known miRNAs that were 
confirmed by qRT-PCR were hsa-miR-3164, hsa-miR-3130-5p, and hsa-miR-3140-3p, hsa-miR-
29c-3p, and hsa-miR-103a-2-5p. The selection of the five known miRNAs was based on the 
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relevance of their targets to KSHV pathogenesis (Table 4). The expression of the known 
miRNAs, hsa-miR-3164, hsa-miR-3130-5p, and hsa-miR-3140-3p were downregulated while 
hsa-miR-29c-3p and hsa-miR-103a-2-5p were upregulated (Fig. 4a). The expression of fourteen 
novel miRNAs were upregulated while the other fourteen were downregulated in KSHV-infected 
BJAB cells (Fig. 4b). We also tested the ability of UV-treated KSHV (UV-KSHV) to alter the 
expression miRNAs during the course of infection. The UV-KSHV was inactivated successfully 
as it could no longer establish an infection in BJAB cells. There was a robust expression of the 
immediate-early gene, ORF50, in KSHV-infected BJAB compared to the UV-KSHV 
(Supplemental Fig. 1). Interestingly, we observed comparable results when BJAB cells were 
infected for 15min PI with UV-KSHV (Supplemental Fig. 2). These results may imply that the 
miRNA-based response to early stages of KSHV infection in cells is purely dependent on 
interactions between the virus envelope-associated and other structural proteins with the host 
cell machinery and not the viral genome. 
To understand the molecular function and biological processes of these known and 
novel miRNAs during early stages of KSHV infection, three independent algorithms, miRanda, 
MIRTar, and DIANA, were used to predict the targets for each of the miRNAs that were 
differentially expressed. The annotated target genes regulated by known miRNAs relevant to 
KSHV pathogenesis were mainly involved in regulating cell signaling, initiating transcription of IE 
genes, promoting latent infection, and modulating the host immune response (Tables 4). We 
identified 84 target genes for 24 (out of a total of 28) of the identified novel miRNAs 
(Supplemental Fig. 3). These predicted target genes for the respective novel miRNAs were 
those that were directly associated with viral uptake. In fact, we validated the expression pattern 
of 4 putative targets of the novel miRNAs by qRT-PCR and Western blotting (Supplemental 
Fig. 4A, B). The paradigm explaining KSHV infection and the resultant changes in the 





Deep sequencing approach has become an effective tool to analyze the expression profiles of 
miRNAs in animals and plants. Cellular miRNAs are implicated in the pathogenesis of numerous 
diseases, including those caused by various pathogens like bacteria and viruses. Some cellular 
miRNAs inhibit virus replication by regulating host immune responses or targeting viruses 
(Slonchak et al., 2014), while other miRNAs can also promote viral replication by modulating the 
cellular environment (Jopling et al., 2005; Norman and Sarnow, 2010). The KSHV genome 
actually encodes for at least 25 mature viral miRNAs (Happel et al., 2016). Recent studies 
unraveled the ability of KSHV miRNAs to regulate latency, angiogenesis, and the spread of the 
infected cells. Likewise, these viral miRNAs interfere with the host immune system by 
modulating both viral and cellular gene expression, and the actual tumorigenesis (Qin et al., 
2017a; Tan et al., 2015). However, little is known about the manner in which the expression 
profile of cellular miRNAs is altered during the early stages of KSHV infection. To this end, we 
used deep sequencing to identify cellular miRNAs with significantly altered abundances in 
response to early stages of KSHV infection of BJAB human B cells. 
 KSHV entry is a rapid process (Akula et al., 2003). In as early as 5min PI, KSHV is 
internalized by endocytosis (Akula et al., 2003) and by 30min PI, KSHV immediate early 
transcript (orf50) is expressed in infected cells (Krishnan et al., 2005). KSHV infection of target 
cells resulted in the generation of various sRNA populations, including siRNAs, miRNA, and 
piRNAs as described earlier (Hussain et al., 2011; Vodovar et al., 2012). In our study, we 
determined KSHV infection of cells as early as 15min PI could significantly alter expression of 
miRNAs. The lengths of the clean reads in KSHV-infected and uninfected cells were mostly 22–
23 nt (Fig. 1) These observations are consistent with previous analyses of miRNAs from 
animals and plants (Jia et al., 2017; Zhang et al., 2015). Our study, for the first time describes 
the expression profiles of both known and novel miRNAs as a result of KSHV infection of cells 
at an early time point. We also observed the typical 26-30nt long sRNAs representing the 
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piRNAs to be altered during early stages of KSHV infection (Table 2). The histone-derived 
piRNAs are dynamically expressed throughout the cell cycle (Girardi et al., 2017), suggesting a 
role for the KSHV-altered piRNA pathway in the regulation of histone gene expression, and 
perhaps also in selectively regulating non-self (viral) genes (Iwasaki et al., 2015). 
 Virus infection of cells can alter many cellular mechanisms including apoptosis and 
replication of the virus genome. Herein, for the first time, we identified the ability of KSHV to 
significantly alter miRNA expression profile as early as 15min PI. In human B cells, a large 
number of miRNAs exhibit altered profiles during early stages of KSHV infection of cells (Fig. 2; 
Table 3). We identified a total of 32 known and 28 novel miRNAs to be differentially expressed 
during KSHV infection of B cells. The results from deep sequencing was authenticated by 
performing qRT-PCR (Fig. 4). Implications of known miRNAs differentially expressed during 
KSHV infection of human B cells is provided in Table 4. Table 4 was constructed based on 
relevant target genes critical to the biology of KSHV internalization. Interestingly, the known 
miRNA, hsa-miR-3164; novel miRNAs, chrX_2892, chr2_257, and chr2_37 were significantly 
down-regulated upon KSHV infection of cells (Fig. 4). Over all, there were miRNAs upregulated 
and downregulated in these cells during KSHV infection. The net proposed effects of these 
miRNAs (both known and novel) are as follows: (i) assists virus entry; (ii) induces critical cell 
signaling; (iii) initiates transcription of IE genes; (iv) promotes latent infection; and (v) protects 
the virus from host immune response. 
 The present study not only describes the manner in which KSHV alters expression of 
miRNAs during as early stages of KSHV infection of BJAB cells but also poses a new question: 
What are the roles of such miRNAs induced specifically by KSHV at such early time points 
during KSHV infection? Changes in the host cell miRNAs in response to virus infection may be 
a mechanism that coordinates gene expression critical to the outcome of a viral pathogen: a 
productive infection versus a robust immune response. Future studies are aimed at 
understanding the regulatory role of miRNAs in the biology of KSHV entry. 
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 In summary, we used deep sequencing to identify and examine the host cell miRNAs 
expressed by BJAB cells that may play a significant role in internalization of KSHV. To our 
knowledge, this is the first study delineating the changes to the miRNA expression profiles as a 
result of early stages of KSHV infection of cells. Such a profiling can help inform additional 
studies to better understand the mechanisms responsible for the specific changes observed in 
the expression of cellular miRNAs and their roles in the of KSHV pathogenesis. 
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Treatment Total Read Clean/trimmed read Percentage 
UnInfected  17,093,083 15,296,253 89.5% 
















miRNA 5,000,000 4,000,000 
rRNA 2,000 2,000 
tRNA 0 0 
piRNA 289,000 167,000 
snoRNA 240,000 130,000 
scRNA 0 0 
snRNA 8,000 8,000 

































Table3: Novel miRNAs altered during KSHV infection of cells. 
ID/Name Sequence Primer 
chr10_2863 GGCGTGGAGCCGGGCT AGATTCTATAGACGCGGCGTGGAGCCG 
chr11_3509 CCGGGAGCCCCCTCCAT ATATTTATAGACGCCCGGGAGCCCCCTC 
chrX_2892 GTTTAGACGGGTTTC GCGACGCGCGCAGACTATTAAGGCTTAG 
chr16_5060 CCAGCCAGGCCCCACCA 
GGAA 













ACGACAGATCATAACCAGCCAGGCCCCA                               
chr17_2719 GGCGGACGCCTGAAGTGT ACACAGATCATACAGGCGGACGCCTGAAG                                







chr2_257 CGGGCGTGGTGGTGGGAA GCAGTCAGATCATAACGGGCGTGGTGGT 




chr6_6774 GAGGTCCCCGGTTTG ACTTGACAGATCACAAGGAGGTCCCCGGT 






































Table 4. Implications of Known miRNAs induced during early stages KSHV infection of 
cells. 
miRNAs Target Function of the target Implications 
Upregulated    
hsa-miR-4742-3p ZFAND5 Bind AU-rich elements (AREs) and 
regulate many inflammatory 
mediators including tumor necrosis 
factor (TNF) and COX2 (He et al., 
2012). 
Inhibits host immune 
response to KSHV infection. 
hsa-miR-29c-3p SPARC Inhibits cell growth and promotes 
apoptosis (Nian et al., 2015). 
Promotes cell survival. 
hsa-miR-449b-5p SIRT1 Induces apoptosis (Ferreira et al., 
2014). 
Promotes cell survival. 
hsa-miR-15a-5p BCL2 Inhibits apoptosis (Vogler et al., 
2017). 
Limit cell division and 
promote viral latency. 
hsa-miR-103a-2-5p NFAT5 Is crucial for immune response and is 
a key regulator of T cell activation 
(Muller and Rao, 2010). 
Limits host cell immune 
response to KSHV infection. 
hsa-miR-1226-5p 
hsa-miR-1343 
SEPT8 Upregulates MAPK signaling 
(Shiryaev et al., 2012). 
Promotes latent infection of 
cells. 
hsa-miR-133a CDC42 Induces filopodial formation and cell 
migration (Ye et al., 2013). 
Inhibits cell migration. 
hsa-miR-1323 PTENP1 Negatively regulates AKT/PKB 
signaling pathway (Song et al., 2012). 
Enhances AKT/PKB 
associated signaling. 
    
Downregulated    
hsa-miR-3164 DCAF7 Regulates protein kinase associated 
signaling  (Glenewinkel et al., 2016). 
Induces intracellular protein 
kinase signaling. 
hsa-miR-3130 ORC4 ORC4 is a component of the Pre-
replicative complex (pre-RC) crucial to 
replication of the genome (Wiebusch 
et al., 2003). 
This may allow for the initial 
lytic replication of the KSHV 
genome that is observed in 
cells. 
hsa-miR-3140-3p DNAJC10 Enhances membrane fusion (Jain et 
al., 2008). 
May assist viral membrane 









Figure 1. Length distribution and count of sRNA sequences. The x-axis indicates length 
distribution of clean sequence reads in two sRNA libraries pooled at 15min PI from uninfected 
and KSHV-infected BJAB cells. The y-axis indicates the count of reads for sequences of each 
length, the most of reads are 22 and 23 nt in length. 
 
Figure 2. Differential expression of known miRNAs. Heat map showing 32 known miRNAs 
that are differentially expressed between uninfected and KSHV-infected BJAB cells at 15min PI. 
Red color indicates highly expressed miRNAs, and miRNAs with low expression are indicated in 
blue. The absolute signal intensity ranged from 0 to 12. 
 
Figure 3. Differential expression of novel miRNAs. Twenty eight differentially expressed 
novel miRNAs between uninfected and KSHV-infected BJAB cells at 15min PI have been 
predicted using miRdeep software. The x-axis indicates the ID/name of novel miRNAs and y-
axis indicates fold change in expression of these miRNAs. Student’s t test was performed to 
compare expression of a specific miRNA in KSHV-infected cells compared to the uninfected 
cells. All the changes plotted are statistically significant (P value of 0.05 or less). 
 
Figure 4. qRT-PCR confirmation of differentially expressed miRNAs. Expression of 
miRNAs detected by next-generation sequencing was confirmed using qRT-PCR. The qRT-
PCR data was plotted for (A) 5 known miRNAs and (B) 28 novel miRNAs that are differentially 
expressed in KSHV-infected BJAB cells compared to uninfected cells at 15min PI. The relative 
expression of miRNAs was measured in terms of threshold cycle value (Ct) and normalized to 
snRNA RNU6B. The x-axis indicates the ID/name of miRNAs and y-axis indicates fold change 
in expression of these miRNAs. Bars represent average ± s.d. of three individual experiments. 
Student’s t test was performed to compare expression of a specific miRNA in KSHV-infected 
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cells compared to the uninfected cells. All the changes plotted are statistically significant (P 
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The supplementary data for this manuscript includes the following and they can be 
downloaded at the following link: 
https://link.springer.com/article/10.1007%2Fs00705-017-3478-y#SupplementaryMaterial 
 
Supplementary Table 1. sRNA candidates in uninfected BJAB cells. 
Supplementary Table 2. sRNA candidates in KSHV-infected BJAB cells. 
Supplementary Table 3. Mature miRNA in uninfected BJAB cells at 15min PI. 
Supplementary Table 4. Mature miRNA in KSHV-infected BJAB cells at 15min PI. 
Supplementary Table 5. Predicted Novel miRNA in KSHV-infected BJAB cells at 15min PI. 
 
Supplementary Figure 1. UV exposure inactivates KSHV. BJAB cells were infected with 
10MOI of KSHV or UV-KSHV for 30 min prior to monitoring infection of cells by qRT-PCR 
conducted to measure the expression of ORF50. Bars represent average ± s.d. of three 
individual experiments. Data was plotted to represent the change in RNA copy numbers of 
KSHV-ORF50 used as an indicator of a successful infection. Student’s t test was performed to 
compare expression of ORF50 RNA in KSHV-infected cells compared to the UV-KSHV infected 
cells. All the changes plotted are statistically significant (P value of 0.05 or less). 
 
Supplementary Figure 2. UV-KSHV modulates expression of miRNAs. The qRT-PCR data 
was plotted for the 28 novel miRNAs that are differentially expressed in UV-KSHV-infected 
BJAB cells compared to uninfected cells at 15min PI. The x-axis indicates the ID/name of novel 
miRNAs and y axis indicates fold change in expression of these miRNAs. The relative 
expression of miRNAs was measured in terms of threshold cycle value (Ct) and normalized to 
snRNA RNU6B. Bars represent average ± s.d. of three individual experiments. Student’s t test 
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was performed to compare expression of a specific miRNA in KSHV-infected cells compared to 
the uninfected cells. All the changes plotted are statistically significant (P value of 0.05 or less). 
 
Supplementary Figure 3. Putative targets for novel miRNAs expressed during early 
stages of KSHV infection of BJAB cells. 24 novel miRNA that are validated to be differentially 
expressed by KSHV infection have been predicted to modulate expression of 84 target genes 
with confirmed roles during early stages of virus infection. MIRanda, DIANA, and miRTar tools 
were used for identifying miRNA-target interactions. 
 
Supplementary Figure 4. Validation of miR-targets by qRT-PCR (A) and Western blotting 
(B). (A) Expression of IRF5, DLG5, CPLX1 and SPTBN4 were detected by qRT-PCR at 15 
minutes post KSHV infection. The qRT-PCR data was plotted for fold changes for the 
expression of IRF5, DLG5, CPLX1, and SPTBN4 in BJAB cells infected with 10 MOI of KSHV 
compared to uninfected cells. Bars represent average ± s.d. of three individual experiments. 
Student’s t test was performed to compare expression of specific target genes in KSHV-infected 
cells compared to the uninfected cells. All the changes plotted are statistically significant (P 
value of 0.05 or less). (B) Western blotting analysis demonstrate changes in the expression 
levels of identified putative targets for novel miRNAs expressed during early stages of KSHV 
infection. BJAB cells were either left uninfected or infected with 10 MOI of KSHV for 30 min. The 
cells were then lysed and the expression of IRF5, DLG5, CPLX1 and SPTBN4 protein levels 
was monitored using appropriate antibodies and normalized to β-actin protein levels. The link 
between miRNAs and putative target genes is depicted by a schematic. Red and green lines 
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Kaposi’s sarcoma-associated herpesvirus (KSHV) is etiologically associated with all forms of 
Kaposi’s sarcoma worldwide. Little is currently known about the role of microRNAs (miRNAs) in 
KSHV entry. We recently demonstrated that KSHV induces a plethora of host cell miRNAs 
during the early stages of infection. In this study, we show the ability of host cell miR-36 to 
specifically inhibit KSHV-induced expression of interferon induced transmembrane protein 1 
(IFITM1) to limit virus infection of cells. Transfecting cells with miR-36 mimic specifically lowered 
IFITM1 expression and thereby significantly dampening KSHV infection. In contrast, inhibition of 
miR-36 using miR-36 inhibitor had the direct opposite effect on KSHV infection of cells, allowing 
enhanced viral infection of cells. The effect of miR-36 on KSHV infection of cells was at a post-
binding stage of virus entry. The highlight of this work was in deciphering a common theme in 
the ability of miR-36 to regulate infection of closely related DNA viruses: KSHV, Epstein-Barr 
virus (EBV), and herpes simplexvirus-2 (HSV-2). Taken together, we report for the first time the 
ability of host cell miRNA to regulate internalization of KSHV, EBV, and HSV-2 in hematopoietic 




Kaposi’s sarcoma-associated herpesvirus (KSHV) causes Kaposi’s sarcoma (KS)(Chang et al., 
1994). To a lesser extent, KSHV is etiologically associated with rare neoplastic disorders like 
primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD)(Soulier et al., 
1995). KS is a malignant vascular tumor characterized by lesions occurring mainly on the skin, 
but can also affect the mucosa and visceral organs(Makharoblidze et al., 2015). Hallmarks of 
KS are angiogenesis, cell proliferation, and inflammation(Cancian et al., 2013). KSHV is among 
the list of viral pathogens estimated to cause 12-25% of human cancers worldwide(Morrison et 
al., 2015). 
 KSHV has a biphasic life cycle comprised of latent and lytic phases of replication that 
are distinguished based on divergent gene expression profiles(Uppal et al., 2015). The 
dynamics between latent and lytic phases of replication allows the virus to persist for the 
duration of the host’s lifetime(Frappier, 2015). Notably, KSHV establishes latency in the majority 
of infected cells(Steitz et al., 2011); at any given instance, only a subpopulation (<3%) of 
infected cells display evidence of lytic gene expression(Sun et al., 1999). MicroRNAs (miRNAs) 
are one of the main classes of non-coding RNAs(Keshavarzi et al., 2017). These are small non-
coding RNAs that regulate expression of genes in cells(Wang et al., 2017). The human genome 
encodes thousands of miRNAs(Kozomara and Griffiths-Jones, 2011). Of late, miRNAs have 
emerged as a pivotal component of host cell responses to a pathogen including viruses, 
bacteria, and fungi(Liu et al., 2017a). 
 KSHV, human immunodeficiency virus 1 (HIV-1), Epstein-Barr virus (EBV), and herpes 
simplex virus type 1 (HSV-1) are few examples of the limited number of viruses that encode 
their own miRNAs(Swaminathan et al., 2013; Zhang et al., 2014). KSHV encodes 12 pre-
miRNAs which are processed to yield 25 mature miRNAs(Qin et al., 2017a). The roles of these 
KSHV-encoded miRNAs is to establish and/or maintain KSHV latency, enhance angiogenesis, 
spread infected cells, and interfere with the host immune system; all of which are crucial to 
49 
 
oncogenesis(Cai et al., 2005). Extensive work has been conducted on KSHV encoded miRNAs 
and the manner by which KSHV replication alters cellular miRNAs(Chen et al., 2016; Tan et al., 
2015). However, there is limited work along the lines of understanding the effects of cellular 
miRNAs in response to early stages of KSHV infection of cells; specifically internalization of the 
virus. Recently, we employed deep sequencing for the first time, to analyze the miRNA 
expression profile in KSHV-infected BJAB cells during early stages of infection(Hussein and 
Akula, 2017c). In this study, we attempted to decipher how the cellular miRNA-36 (miR-36) 
alters KSHV infection in physiologically relevant cells: human B, and endothelial cells. We 
focused on the expression and effects of cellular miR-36 in response to KSHV infection because 
it was consistently elevated at 15 and 30min post infection (PI). Our data showed that the over-
expression of cellular miR-36 inhibits KSHV infection of cells by dampening expression of 
interferon induced transmembrane protein 1 (IFITM1). Interestingly, the effect of IFITM1 on the 
closely related virus, Epstein-Barr virus (EBV) and a distant relative, herpes simplex virus-2 
(HSV-2) followed the same pattern as in KSHV. These results reveal a layer of common theme 




KSHV infection of cells induces host cell miR-36 during early stages of KSHV infection 
In a recently concluded study, we described a significant increase in the expression of host cell 
encoded miR-36 as early as 15 min PI of cells(Hussein and Akula, 2017c). In the present study, 
we monitored expression of this miR-36 at early time points during KSHV infection of human B 
and endothelial cells. We employed human B (BJAB) and endothelial (HMVEC-d) cells as they 
are physiologically relevant cells to KSHV biology. Expression of miR-36 gradually increased 
from 5min PI and peaked at 30min PI in KSHV infected BJAB (Fig. 1A) and HMVEC-d cells 
(Fig. 1B). Uninfected BJAB and HMVEC-d cells did not express miR-36 (Fig. 1A, B). 
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Expression of known miRNAs, hsa-let-7c and hsa-miR-3130-5p, were not significantly altered 
when compared to miR-36 during early stages of KSHV infection of cells (Fig. 1A, B). 
Treatment of cells with 10units/ml of heparinase I/III for 2h at 37C prior to KSHV infection of 
cells resulted in a significant drop in the expression of miR-36 in BJAB (Fig. 1C) and HMVEC-d 
cells (Fig. 1D). Also, infection of both BJAB and HMVEC-d cells with UV.KSHV could induce the 
expression of miR-36 to comparable levels as the wild-type KSHV (Fig. 1C, D). These results 
demonstrate KSHV to induce host cell miR-36 very early upon infection. The key features of 
miR-36 including the secondary structure are provided in Table 1 and supplemental Figure 1, 
respectively.  
 
miR-36 inhibits KSHV infection in BJAB and HMVEC-d cells 
To evaluate the biological effects of miR-36 in target cells, we analyzed the effects of miR-36 
mimic and inhibitor on KSHV infection. The range of doses tested in this study is comparable to 
those reported in the earlier studies(Jin et al., 2015; Montgomery et al., 2014; Noh et al., 2017; 
Seimandi et al., 2005; Shao et al., 2017). The doses of the mimic and inhibitor used in the study 
did not significantly induce cell death in BJAB and HMVEC-d cells (Fig. 2A, B). Transfection of 
BJAB (Fig. 2C) and HMVEC-d (Fig. 2D) cells with miR-36 mimic significantly reduced KSHV 
infection of cells as monitored by the expression of ORF50 gene as early as 30min PI. KSHV 
entry is a quick process and the IE gene, ORF50, is expressed immediately upon 
infection(Dyson et al., 2010). KSHV infection was not significantly altered in BJAB (Fig. 2C) and 
HMVEC-d (Fig. 2D) cells that were either transfected with scrambled miRNA control (miR-NC) 
or mock transfected. Interestingly, the effect of miR-36 mimic on KSHV infection of BJAB and 
HMVEC-d cells could be significantly reversed by co-transfecting cells with 10nM of miR-36 
inhibitor (Fig. 2E). Co-transfection of cells with miR-NS did not alter the effects of miR-36 mimic 
(Fig. 2E). To ascertain that the effect of miR-36 mimic was at a post-binding stage of infection, 
we performed a binding assay. The binding assay performed on BJAB and HMVEC-d cells 
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demonstrated that miR-36 mimic and the miR-36 inhibitor did not block KSHV from binding the 
target cells (Fig. 2F). Incubating KSHV with heparin but not CSA significantly blocked KSHV 
from binding cells (Fig. 2F). Our results clearly implicate miR-36 to inhibit KSHV infection of 
cells. To extend our understanding of the role of miR-36 on other related viruses, we tested the 
effect of miR-36 mimic and the miR-36 inhibitor on EBV and HSV-2 infection of BJAB cells. 
Interestingly, miR-36 mimic could significantly block EBV and HSV-2 infection of BJAB cells and 
this inhibition could be specifically reversed by the miR-inhibitor (Fig. 3). 
 
miR-36 targets IFITM1 
By using the DIANA and MiRmap tool algorithms, we identified a putative miR-36 binding site 
located in the 3’-UTR of IFITM1 mRNA (Supplemental Figure 2). To confirm the ability of miR-
36 to specifically inhibit IFITM1 expression, we monitored the expression of IFITM1 in target 
cells that were untransfected, transfected with miR-36 mimic, or miR-NC prior to infection. 
Transfection of BJAB and HMVEC-d cells with miR-36 mimic significantly lowered the 
expression of IFITM1 at 15min PI compared to untransfected cells and cells transfected with 
miR-NC (Fig. 4A). Transfection of cells with miR-36 mimic could specifically inhibit IFITM1 
expression from 5min till 48h PI (data not shown). These results authenticate the fact that 
IFITM1 expression may well be regulated by miR-36. 
 In order to determine the bona fide target of miR-36, a luciferase reporter assay was 
performed. In this assay, two quantifiable genes encoding luciferase proteins were put on a 
vector. The IFITM1 3′ UTR with the target region was placed downstream GLuc to regulate its 
translation, and SEAP was placed under no regulation for normalization. 293 cells were co-
transfected with the IFITM1 3′ UTR vector plasmid and miR-36 mimic. miR-36 mimic 
significantly decreased the relative luciferase activity compared to the cells that were 
transfected with miR-NC (Fig. 4B). In contrast, transfection of cells with miR-inihibitor 
reversed the ability of miR-36 mimic from lowering the luciferase activity (Fig. 4B). There was 
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an inverse correlation observed in the expression of miR-36 and IFITM1 during the course of 
KSHV infection of BJAB (Fig. 4C) and HMVEC-d (Fig. 4D) cells. These results suggest that 
miR-36 directly targets IFITM1 and thereby downregulates its expression. 
 
IFITM1 expression enhances KSHV, EBV, and HSV-2 infection of cells 
IFITM1 protein expression was significantly elevated with KSHV infection of BJAB and HMVEC-
d cells (Fig. 5A). The expression of IFITM1 increased in KSHV infected cells as early as 5min 
PI which was elevated by 15min and 10min PI in BJAB and HMVEC-d cells, respectively, but 
declined sharply by 30 min PI (Fig. 5A). To confirm a role for IFITM1 in KSHV infection of target 
cells, we transiently transfected BJAB and HMVEC-d cells with pQCXIP/IFITM1 and the 
expression of IFITM1 was confirmed by flow cytometry (Fig. 5B). KSHV infection of the above 
IFITM1 expressing BJAB and HMVEC-d cells was a measure of the expression of ORF50 at 
30min PI. The idea was to strictly understand the effects of IFITM1 expression on early stages 
of KSHV infection. BJAB (Fig. 5C) and HMVEC-d (Fig. 5D) cells expressing IFITM1 supported 
a significantly enhanced KSHV infection compared to those cells that were left untransfected, 
mock transfected, or transfected with the empty vector. Surprisingly, IFITM1 expression also 
enhanced HSV-2 and EBV infection of BJAB and HMVEC-d cells (Fig. 5C, D). Interestingly, co-
transfection of the above cells with miR-36 mimic could significantly drop KSHV infection of cells 
compared to miR-NC (Fig. 5C, D). 
 To further confirm the role of IFITM1 in KSHV infection of cells, we first transfected cells 
with siRNA specific for IFITM1. Northern blotting was performed at 0, 12, 24, and 48 hours after 
transfection as per the standard protocols to monitor IFITM1 mRNA expression (Fig. 6A). The 
levels of IFITM1 mRNA was significantly suppressed in BJAB and HMVEC-d cells by siRNA 
when compared with a (NS)siRNA control (Fig. 6A). A IFITM1 mRNA inhibition of 82% ± 7%, 
74% ± 9%, and 45% ± 6% was observed in BJAB cells at 12, 24, and 48 hours, respectively, 
after siRNA transfection (Fig. 6A). A IFITM1 mRNA inhibition of 78% ± 9%, 65% ± 7%, and 34% 
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± 7% was observed in HMVEC-d cells at 12, 24, and 48 hours, respectively, after siRNA 
transfection. IFITM1 expression levels were not significantly altered by the (NS)siRNA controls 
in both the cells tested, demonstrating the specificity of the siRNA used (Fig. 6A). IFITM1 
expression in target cells transfected with siRNA specific to IFITM1 was significantly lowered at 
15min post KSHV infection (Fig. 6B). In contrast, KSHV induced IFITM1 expression in 
untransfected or cells transfected with (NS)siRNA were not altered (Fig. 6B). On the same 
lines, KSHV infection in cells silenced for the expression of IFITM1 was significantly lower 
compared to cells that were untransfected or transfected with (NS)siRNA (Fig. 6C). Silencing 
the expression of IFITM1 also decreased EBV and HSV-2 infection of the above cells (Fig. 6C). 
The above viral infections were monitored by performing qRT-PCR. Taken together, the results 
clearly implicate a role for IFITM1 in enhancing KSHV, EBV, and HSV-2 infection of cells. 
 
DISCUSSION 
Since miRNAs discovery over 20 years ago, miRNAs have been established as key players in 
the molecular mechanisms of mammalian biology including the maintenance of normal 
homeostasis and the regulation of disease pathogenesis. Host miRNAs also play a crucial role 
in mounting an immune response against microbial infections including those caused by 
viruses(Eulalio et al., 2012). Several viruses belonging to herpesvirus, polyomavirus, 
hepadnavirus, adenovirus, and retrovirus encode miRNAs(Swaminathan et al., 2013; Zhang et 
al., 2014). Virus-encoded miRNAs (vmiRNA) identified in virus-infected cells significantly 
influence viral replication and disease progression by modulating viral as well as host cellular 
mRNA. Many of the cellular miRNAs affect viral replication either directly by binding to the viral 
genome or indirectly by targeting host factors related to replication(Shrivastava et al., 2015). 
There are several published works that describe virus and cellular encoded miRNAs in KSHV 
pathogenesis(Chen et al., 2016; Keshavarzi et al., 2017). However, to date, there is no report 
on the role of cellular miRNAs during early stages of KSHV infection. 
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 Recent studies from our laboratory using a combination of deep sequencing and qRT-
PCR identified cellular miR-36 to activate as early as 15min PI(Hussein and Akula, 2017c). In 
the current studies, we employed physiologically relevant human B cells (BJAB) and endothelial 
cells (HMVEC-d) to make the study more meaningful to KSHV biology. Accordingly, using 
specific primers we analyzed the expression profile of cellular miR-36 during the first 30min of 
KSHV infection of cells. A successful viral entry was a measure of KSHV to enter cells and 
express immediate early gene, ORF50. The expression of ORF50 was monitored by qRT-
PCR(Dyson et al., 2010; Walker et al., 2014). KSHV infection of BJAB and HMVEC-d cells 
rapidly triggered the expression of miR-36 as early as 5min PI that peaked at 30min PI (Fig. 1). 
Expression of miR-36 in KSHV infected BJAB is higher than those in HMVEC cells. This could 
be attributed to the inherited variations observed between different cells in the manner by which 
they respond to virus infection(Maisch et al., 2002). Moreover, the expression level of miRNAs 
has been shown to vary among tissues, cell types, and even between cells of the same 
lineage(Lagos-Quintana et al., 2002; Teruel-Montoya et al., 2014). 
Cellular miR-36 is triggered by UV.KSHV infection of cells while treating target cells with 
heparinase I/III prior to infecting cells with the wild-type KSHV failed to induce expression of 
miR-36. Treatment of cells with heparinase I/III cleave heparan sulfate (HS) at different sites 
and liberate them from the cell surface(Stringer and Gallagher, 1997). KSHV binds to a target 
cell via interacting with HS expressed on the cell surface(Akula et al., 2001b). Taken together, 
our results indicate the following: (i) it is the interactions between the virus envelope proteins 
and the host cells that trigger miR-36 response; and (ii) binding of KSHV to cells is critical to 
miR-36 expression in cells. miR-36 mimic specifically inhibited KSHV infection of BJAB and 
HMVEC-d cells (Fig. 2C, D). Transfection of cells with miR-36 inhibitor reversed the effects of 
miR-36 mimic on KSHV infection of cells (Fig. 2E). The effects of miR-36 mimic and inhibitor 
was specific as the scramble negative control (miR-NC) and non-specific inhibitor (miR-NS) did 
not significantly alter KSHV infection of cells (Fig. 2C, D, E). It was concluded that the effects of 
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miR-36 mimic and inhibitor on KSHV infection was at a post attachment stage of internalization 
as they did not adversely affect virus binding to cells (Fig. 2F). 
 In this study, we originally wanted to use two relevant viruses as negative controls to 
better understand the specificity of miR-36 on KSHV infection of cells. EBV and HSV-2 were 
selected as controls: EBV, like KSHV, belongs to γ-herpesvirinae while HSV-2 belongs to α-
herpesvirinae. Interestingly, we observed a similar effect of miR-36 mimic and inhibitor on EBV 
and HSV-2 infection of cells (Fig. 2F). This could be due to the fact that α, β, and γ-
herpesviruses exhibit and share a common three-dimensional capsid structure along with the 
fact that there is quite a bit of homology in the glycoproteins being expressed on the viral 
envelope(Liu and Zhou, 2007). 
 One miRNA may regulate many genes as its targets, while one gene may also be 
targeted by many miRNAs(Hashimoto et al., 2013). Accordingly, miR-36 can possibly target 
several genes (Supplemental Figure 6). Using bioinformatics tools, we identified IFITM1 to be 
the most promising targets to miR-36. IFITM is a member of the interferon-induced 125–133 
amino acid protein family including IFITM1, IFITM2, IFITM3, IFITM5 and IFITM10. This family of 
proteins is located on chromosome 11 of the human genome and originally described as highly 
inducible genes by α- and γ-interferons (IFNs)(Hickford et al., 2012; Reid et al., 1989). The three 
members of the IFITM proteins (IFITM1, IFITM2, and IFITM3) have gained prominence as novel 
antiviral IFN-stimulated genes (ISGs)(Weidner et al., 2010). Hence, we set out to test the effect 
of transfecting target cells with IFITM1-3 genes on KSHV infection of target cells. Over-
expressing IFITM1 significantly enhanced KSHV infection of cells; IFITM3 moderately enhanced 
KSHV infection while IFITM2 did not alter the viral infection (Supplemental Figure 7). Based on 
these results, we focused our further studies on IFITM1 in terms of miR-36 and early stages of 
KSHV infection. Using bioinformatic tools it was determined that the miR-36 target IFITM1 
expression. Luciferase assay demonstrated the ability of miR-36 to physically interact with 
IFITM1 (Fig. 4B). miR-36 mimic specifically inhibited IFITM1 expression that could be reverted 
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by transfecting cells with miR-36 inhibitor (Fig. 4B). There was an apparent inverse correlation 
observed between the KSHV-induced IFITM1 expression and miR-36 response (Fig. 4C, D). 
We propose the sharp decline in the expression of IFITM1 30min PI is because of an increase 
in the expression of miR-36 (Fig. 4C, D). Taken together, our study established a direct 
association between virus-induced IFITM1 and endogenous miR-36 expression in the biology of 
KSHV.  
IFITM1 is expressed in many cell types including leukocytes and endothelial 
cells(Hickford et al., 2012; Lewin et al., 1991). IFITM1 modulates cell functions including 
immunological responses, cell proliferation, cell adhesion, and germ cell maturation(Bailey et 
al., 2014). As other IFITM proteins, IFITM1 is significantly upregulated by interferons type I 
and II and is critical for anti-virus response of innate immunity(Brass et al., 2009). Recent 
reports indicate IFITM1 to play a significant role in virus entry. IFITM1 inhibits entry of many 
RNA viruses including influenza A H1N1 Virus, West Nile Virus, Dengue Virus, HIV, and 
HCV(Brass et al., 2009; Narayana et al., 2015; Yu et al., 2015a). The suggested mechanisms 
by which IFITM proteins restrict the above virus infections include inhibition of virus binding to 
corresponding cellular receptors, inhibition of endocytosis, and acting as pattern recognition 
receptors by sensing virus infection and activation of downstream cellular signaling 
pathways(Brass et al., 2009). These proteins inhibit fusion of viral membranes with cellular 
endosomal vesicular membranes by blocking the creation of hemifusion, reducing membrane 
fluidity and curvature, and by possibly disrupting intracellular cholesterol homeostasis(Amini-
Bavil-Olyaee et al., 2013; Li et al., 2013a). However, IFITMs can also enhance viral infection 
of cells: (i) both IFITM1 and IFITM3 modestly enhanced human papillomavirus 16 (HPV-16) 
infection of a variety of cells(Warren et al., 2014); and (ii) Zhao et al have shown type I IFN-α, 
IFN-γ, and type II IFN-λ to significantly promote infection of  human coronavirus, HCoV-OC43 
by the induction of IFITM proteins. The authors reported that the over-expression of IFITM3 
57 
 
significantly increased susceptibility of Huh7.5 cells to HCoV-OC43 infection(Zhao et al., 
2014). In general, the IFITM family of proteins affects virus entry of cells. Over-expression of 
IFITM1 significantly enhanced KSHV infection of target cells (Fig. 5C, D) while silencing 
expression of IFITM1 had the opposite effect (Fig. 6). More interestingly, we observed 
identical effects of IFITM1 in enhancing EBV and HSV-2 infection of cells (Fig. 6C). 
IFNs are generally considered to be antiviral cytokines that inhibit virus infection of 
cells by stimulating ISGs(Samuel, 2001). In fact, we observed a significant increase in the 
expression of IFN-α and - during the early stages of KSHV infection of BJAB and HMVEC-d 
cells (Supplemental Figure 8). If that is the case, how can IFITM1 enhance infection of not 
just KSHV; but also of EBV and HSV-2? Such a scenario can be possible only if the virus 
infection is not altered by IFNs and associated proteins(Zhao et al., 2014). Interestingly 
enough, herpesviruses as a group (including KSHV) is considered to be relatively insensitive 
to the antiviral effects of IFNs in a variety of different cell systems(Adams et al., 1975; Flowers 
et al., 1998). In a way, our results demonstrate for the first time that herpesviruses, KSHV, 
EBV, and HSV-2, not only hijack IFITM1 to their benefit in facilitating virus entry into cells but 
also evade the IFN-induced antiviral effects. 
This study provides a new insight to virus infection. KSHV (including EBV and HSV-2) 
interactions with target cells induce IFITM1 within minutes, which facilitate virus entry into 
cells. KSHV-induced IFITM1 is part of the innate immune activation system that occurs in an 
antigen-independent fashion(Schoggins and Rice, 2011) and relies on the ability of the host 
to recognize virus via specific pattern recognition receptors(Takeuchi and Akira, 2010). To 
counter the effects of KSHV-induced IFITM1, infected cells respond within a short period of 
time by inducing expression of miR-36. Cellular miR-36 in turn inhibits expression of IFITM1 
and thus limit virus infection of cells. Perhaps, this could be a mechanism of superinfection 
resistance (SIR)(Nethe et al., 2005) developed by cells towards KSHV and other related viral 
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pathogens. IFITM1 suppression by miR-36 may have direct and indirect effects of KSHV 
pathobiology: (i) directly limit KSHV infection of cells; (ii) block cell proliferation/division(Jin et 
al., 2017) and thereby promote KSHV latency(Zhi et al., 2015); and (iii) reduce virus-induced 
inflammation. Such effects of IFITM1 on the biology of KSHV will be better understood by 
employing the three-dimensional (3-D) cell culture models as they mimic certain aspects of 
the tissue environment(Cheng et al., 2011; El Assal et al., 2016). For all this time, studies on 
virus entry have always focused primarily on the roles of virus encoded glycoproteins and 
their cognate host cell receptors. To our knowledge, this is the first report of a miRNA 
influencing KSHV infection of cells and this, we hope, will open doors to a further 
understanding of virus entry; after all, it is the miRNAs that regulate the gene function. 
Of late, miRNA-based therapeutics have been used to effectively treat autoimmune 
diseases(Wang et al., 2015), and cancers including prostate cancer, and leukemia(Braicu et al., 
2013) in animal models. The fact that miRNAs can influence virus entry is fascinating as 
miRNA-based therapeutics like the use of miR-mimics can effectively be used to treat virus 
entry including pathogenesis. There are several questions that need to be answered and they 
are as follows: (i) How does IFITM1 enhance KSHV infection of cells? Does it physically bind 
KSHV envelope-associated protein and facilitate endocytosis? (ii) What is the role of host cell 
receptors in the IFITM1-facilitated virus entry? (iii) What is the dynamics between the 
expression pattern of IFITM1 and 3 in regulating KSHV infection of cells? And (iv) Can induction 
of miR-36 by KSHV infection prevent infected cells from being superinfected with KSHV and 







MATERIALS AND METHODS 
Cells 
Human Burkitt lymphoma B cell line (BJAB), human foreskin fibroblasts (HFFs; 
Clonetics,Walkersville, MD), HEK-293 (293), and dermal microvascular endothelial cells 
(HMVEC-ds; CC-2543; Clonetics) were used in this study. BJAB cells were propagated in 
phenol red–free RPMI medium (Invitrogen, Carlsbad, CA) while HFF and 293 cells were 
cultured in Dulbecco modified Eagle medium (DMEM) containing 10% charcoal-stripped fetal 
bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA), L-glutamine, and antibiotics(Akula 
et al., 2005). HMVEC-d cells were propagated in EGM MV-microvascular endothelial cell 
medium (Clonetics) as per standard protocols. The passage numbers for HFFs and HMVEC-ds 
used in this study ranged between 6 - 10, and 5 - 9, respectively. All the cells used in this study 
were negative for mycoplasma as tested by Mycoplasma PCR ELISA, Roche Life Science. For 
culture conditions, refer to supplemental data.  
 
Virus 
The viruses used in this study were wild-type KSHV(Dyson et al., 2010), herpes simplexvirus-2 
(HSV-2)(Akula et al., 2003), and Epstein-Barr virus (EBV)(Bentz et al., 2010). We generated 
ultraviolet (UV) inactivated KSHV (UV.KSHV) as per early studies(Hussein and Akula, 2017c). 
 
Cytotoxicity assay 
The LDH assay was performed using the CytoTox 96 non-radioactive kit (Promega) as per 
earlier studies(Dyson et al., 2010). Target cells were treated with different concentrations of 
miR-36 mimic and inhibitor at 37°C in a V-bottom 96-well plate. After a 24h incubation, the cells 
were analyzed for the expression of LDH, as an indicator of cell death. The LDH assay was 
performed using the CytoTox 96 non-radioactive kit (Promega) as per earlier studies(Dyson et 
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al., 2010). G418 (Sigma-Aldridge, St. Louis, MO) and cytochalasin D (Sigma-Aldridge) were 
used as known cell death inducers. 
 
Virus infection of cells, RNA extraction, and monitoring virus infection 
BJAB, HFF, and HMVEC-d cells were infected with 10 multiplicity of infection (MOI)(Walker et 
al., 2014) of KSHV, EBV, and HSV-2. The cells were left uninfected or infected for 5, 10, 15, 
and 30min prior to washing the cells twice in PBS and processed appropriately for RNA 
extraction. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA). The RNA 
concentration was measured with a NanoDrop ND-2000 spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA), and then verified for quality using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). Only the RNA samples with 260/280 ratios of 1.8 to 2.0 were 
used in the study. 
 Extracted RNA was used to synthesize cDNA and the expression of ORF50 was 
monitored by qRT-PCR using specific primers as per earlier studies(Dyson et al., 2010) 
Expression of ORF50 was used as a scale to measure KSHV infection of cells. As reported 
earlier(Walker et al., 2014), the lowest limit of detection in the standard samples was 6–60 
copies for the ORF50 gene. The results from the use of ORF50 primers were consistently 
confirmed by monitoring the expression of another viral immediate early (IE) gene, vGPCR 
(data not shown). EBV and HSV-2 infection was monitored using specific primers to BRLF1 
(homolog of KSHV ORF50)(Robinson et al., 2011) and HSV-2 IE gene, US1(Kaneko et al., 
2008). 
 
Transfections of cDNA and miRNA 
Target cells were transiently transfected with plasmid DNA using FuGene HD (Promega, 
Madison, WI) as per manufacturer’s recommendations. The plasmid, pQCXIP encoding 
IFITM1, used in this study was kindly gifted to us by Dr. Michael Farzan (The Scripps Research 
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Institute, Jupiter, USA). FuGene HD/DNA ratios of 3:1 for adherent cell lines and 6:1 for 
suspension cell lines were used. Transfection of target cells with different concentrations of 
miR-36 mimic, or scramble control (miR-NC); miRNA inhibitor to miR-36 and non-specific (NS) 
inhibitor (Sigma-Aldridge) was achieved using FuGene HD reagent as per standard laboratory 
procedures. These were transient transfections and experiments using these cells were 
conducted 48h post transfection. 
 
Binding assay 
The effect of miR-mimic and inhibitor on KSHV binding to target cells was assessed by PCR 
detecting the cell-bound KSHV DNA. Briefly, untransfected cells or cells transfected with miR-
mimic or inhibitor were infected with 10MOI of KSHV at +4C. After 60min of incubation with 
virus, cells were washed three times with PBS to remove the unbound virus. Cells were 
pelleted, and total DNA including those representing the cell bound KSHV was isolated using 
DNeasy kit (Qiagen, Valencia, CA) and subjected to qPCR analysis monitoring ORF50 
according to recently published work(Walker et al., 2014). Incubating KSHV with 100µg/ml of 
heparin and chondroitin sulfate A (CSA; Sigma-Aldridge) for 1h at 37C were used as known 
positive and negative controls. 
 
Flow cytometry 
Flow cytometry was used to monitor expression of IFITM1 in the cells as per earlier 
protocols(Walker et al., 2014). Briefly, target cells were fixed in 10ml of ice-cold acetone for 
20min, washed thrice in PBS prior to incubating cells in 25µg/ml of rabbit polyclonal antibody to 
IFITM1 (EMD Millipore, Billerica, MA) for 60min at 4°C. The cells were washed thrice in PBS 
and further incubated with FITC conjugated appropriate secondary IgG at 4°C for 30 min, 
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All the buffers used in this project were made with water that was endotoxin and pyrogen free. 
Western blotting was conducted as per earlier studies(Walker et al., 2014) using the following 
primary antibodies: rabbit anti-IFITM1 polyclonal antibody (EMD Millipore) and mouse anti-actin 
antibodies (Clone AC-74; Sigma-Aldridge). 
 
Real-time qRT-PCR analysis of the expression of miRNAs and IFNs 
The quality of RNA was tested using a spectrophotometer. Only the RNA samples with 260/280 
ratios of 1.8 to 2.0 were used in the study. Approximately 500ng of RNA was reverse 
transcribed in a 25µl reaction volume using the All-in-oneTM miRNA qRT-PCR detection kit 
(GeneCopoeia, Rockville, MD). Briefly, the cDNA was synthesized in a 25μl reaction mix 
containing 5μl of 5x reaction buffer, 2.5U/μl Poly A Polymerase, 10ng/μl MS2 RNA, and 1µl 
RTase Mix. The reaction was performed at 37°C for 60 min and terminated at 85°C for 5 min. 
cDNA that was produced in the RT reaction was diluted ten-fold and was used as the template 
for the PCR reaction in an Applied Biosystems ViiA 7 Real-Time PCR System (Life 
Technologies, USA). In this system, MS2 RNA was used as an external reference for the quality 
of the extracted miRNAs, and RNU6B, RNU44, RNU48, and RNU49 were used for 
normalization. The expression levels of miRNAs were measured employing qRT-PCR with the 
SYBR green detection and specific forward primer for the mature miRNA sequence and the 
universal adaptor reverse primer (GeneCopoeia, USA). Expression of IFN-α, -β, and - by qRT-
PCR was conducted as per earlier protocols(Dyson et al., 2010) using appropriate 




Dual-luciferase reporter assay 
Luciferase reporter plasmids with wild-type IFITM1 3′-UTR were purchased from GeneCopoeia 
(Rockville, MD). 293 cells were plated onto 6-well plates. At 24h post-plating, 293 cells were co-
transfected with IFITM1 3′-UTR luciferase reporter plasmid and miR-36 mimic or miR-NCNA 
scramble control (miR-NC) using FuGene HD (Promega). At 12, 24, 48h post transfection, 
supernatants were collected from each treatment and the luciferase activity measured using the 




Northern blotting to monitor IFITM1 and β-actin expression was performed using a DIG 
Luminescent Detection Kit (Roche, Indianapolis, IN) as per the manufacturer’s 
recommendations(Dyson et al., 2010). 
 
Silencing IFITM1 using siRNA 
Expression of IFITM1 was inhibited by the transfection of double-stranded (ds) RNA oligos as 
per standard protocols(Dyson et al., 2010). IFITM1 siRNA was purchased from Dharmacon 
RNA Technologies (Lafayette, CO). Briefly, 1 x 106 cells were washed twice in RPMI and 
incubated in phenol red–free RPMI supplemented with 5% FBS at 37°C. After 24 hours 
incubation (considered as 0h for experiments in Fig. 6A), the target cells were transfected with 
either ds short interfering RNAs (siRNAs) or the nonspecific (NS) controls using Fugene HD as 
per manufacturer’s recommendations (Promega). At 0, 12, 24, and 48 hours after transfection, 
total RNA was isolated from the cells and subjected to Northern blotting to monitor the 
expression of IFITM1 and β-actin mRNA as per the protocol mentioned in the “Materials and 
methods” section describing Northern blotting. In another set of experiments, untransfected cells 
and cells transfected with siRNA or (NS)siRNA for 12h were infected with 10 MOI of KSHV. At 
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Figure 1. KSHV induces the expression of miR-36 at an early stage of infection. 
Expression of miR-36, has-let-7c, and has-miR-3130-5p were detected by qRT-PCR at different 
time points post-infection in cells infected with 10 MOI of KSHV compared to uninfected cells. 
The qRT-PCR data was plotted for fold changes in the expression of miR-36, has-let-7c and 
has-miR-3130-5p in (A) BJAB cells, and (B) HMVEC-d. BJAB (C) and HMVEC-d (D) cells were 
either untreated or treated with heparinase I/III prior to performing the infection assay followed 
by monitoring the expression of miR-36. UV.KSHV was used in this study as a control to 
understand the importance of an intact virus envelope and associated proteins in inducing miR-
36. The relative expression of miRNAs was measured in terms of cycle threshold value (Ct) and 
normalized to snRNA RNU6B. The x-axis indicates the time points post KSHV infection in 
minutes and y-axis indicates fold change in the expression of miR-36. Bars (panels A, B, C, D) 
represent average ± s.d. of five individual experiments. (A, B) Student t test was performed to 
compare expression of miR-36 in uninfected cells versus 5, 10, 15, and 30min PI. In panels ‘C 
and D’, Student t test was performed to study the effect of HS and compare infection of cells 
with KSHV versus UV.KSHV on miR-36 expression at 5, 10, 15, and 30min PI. Two-tailed P 
value of 0.05 or less was considered statistically significant. *p<0.05; **p,0.01; ***p<0.001; NS-
not significant. 
 
Figure 2. miR-36 overexpression inhibits KSHV infection of cells. To determine the 
cytotoxic effect of miR-36 mimic and inhibitor, cells were transfected with different 
concentrations of miR-36 mimic and inhibitor. At 24h post transfection, lactate dehydrogenase 
release as an indicator of percentage of cell death was monitored for miR-36 mimic (miR-mimic) 
(A) and miR-inhibitor (B). Known inducers of cell death, 1 mg/ml G418 in the case of BJAB cells 
and 2.5 µg/ml Cytochalasin D for HMVEC-d, were used as positive controls in this study. (C-D) 
Transfection of cells with miR-36 mimic specifically inhibit KSHV infection of cells. (C) 
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BJAB and (D) HMVEC-d cells were either untransfected, mock transfected, or transiently 
transfected with different concentrations of miR-36 mimic or control mimic (miR-NC) before 
infection with 10 MOI of KSHV. Data was plotted to represent the percentage of KSHV infection 
as determined by monitoring the change in KSHV-ORF50 RNA copy numbers that were 
detected in transfected cells compared to that detected in untransfected cells (1905 KSHV-
ORF50 RNA copies). Expression of ORF50 was used as a scale to measure KSHV infection of 
cells. As reported earlier(Walker et al., 2014), the lowest limit of detection in the standard 
samples was 6–60 copies for the ORF50 gene. (E) Transfection of cells with miR-36 
inhibitor opposes the effects of miR-36 mimic on KSHV infection of cells. BJAB and 
HMVEC-d were either untransfected, mock transfected, transiently transfected with miR-36 
mimic, co-transfected with miR-36 mimic and miR-36 inhibitor (miR-mimic+mir-inhib), or co-
transfected with miR-36 mimic and nonspecific inhibitor (miR-mimic+mir-NS) before infection 
with KSHV. Data was plotted to represent the percentage of KSHV infection in transfected cells 
compared to untransfected cells. The x-axis indicates the transfection and y-axis indicates the 
percentage of KSHV infection. (F) miR-36 mimic inhibition of KSHV infection of cells is at a 
post-attachment stage of virus entry. KSHV binding to BJAB and HMVEC-d that were 
untransfected, mock transfected, transiently transfected with miR-36 mimic, co-transfected with 
miR-36 mimic and miR-36 inhibitor(miR-mimic+mir-inhib), co-transfected with miR-36 mimic and 
nonspecific inhibitor (miR-mimic+mir-NS), or untransfected and treated with Heparin or CSA. 
Data was plotted to represent the percentage of KSHV binding to target cells treated differently 
compared to the untransfected cells. Bars (panels A-F) represent average ± s.d. of five 
individual experiments. Student t test was performed to compare groups. Two-tailed P value of 





Figure 3. miR-36 overexpression inhibits EBV and HSV-2 infection of BJAB cells. BJAB 
was either untransfected, mock transfected, transiently transfected with miR-36 mimic (miR-
mimic), co-transfected with miR-36 mimic and miR-36 inhibitor (miR-mimic+mir-inhib), or co-
transfected with miR-36 mimic and nonspecific inhibitor (miR-mimic+mir-NS) prior to infecting 
the cells with 10 MOI of EBV or HSV-2. Data was plotted to represent the percentage of virus 
infection as determined by monitoring the change in RNA copy numbers of EBV-BRLF1 or HSV-
2 US1 as detected in transfected cells compared to that detected in untransfected cells (1750 
copies of EBV BRLF-1 and 2678 copies of HSV-2 US1). Bars represent average ± s.d. of five 
individual experiments. Student t test was performed to compare viral infection of untransfected 
cells versus cells transfected with miR-36 mimic, inhibitor, miR-NS, or mock transfected cells. 
Two-tailed P value of 0.05 or less was considered statistically significant. ***p<0.001; NS-not 
significant. 
 
Figure 4. miR-36 targets IFITM1. (A) miR-36 mimic lowers KSHV-induced IFITM1 
expression. Western blotting analysis demonstrate a decrease in IFITM1 protein levels upon 
over-expression of miR-36 mimic. BJAB and HMVEC-d cells were either untransfected, 
transiently transfected with miR-36 mimic, or transfected with control mimic (miR-NC) prior to 
infecting cells with 10 MOI of KSHV. Monitoring IFITM1 protein levels was performed 15 
minutes post KSHV infection and normalized to β-actin protein levels. Data representing the 
IFITM1 protein expression levels are presented as fold increase (average±s.d. from three 
experiments) in the boxes below the panels. The results presented are a representative data 
and the original full-length blots of the cropped images is provided in Supplemental Figure 3. 
(B) miR-36 specifically binds and interact with IFITM1. Luciferase activity in 293 cells 
transfected with Dual-luciferase vector encoding Gaussia Luciferase (GLuc) and secreted 
alkaline phosphatase (SEAP) with 3'UR of IFITM placed downstream of Glu luciferase reporter 
(IFITM1 3'UTR). 293 cells were either transfected with IFITM1 3'UTR, co-transfected with 
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IFITM1 3'UTR and miR-36 mimic, co-transfected with IFITM1 3'UTR and control mimic (miR-
NC), or co-transfected with IFITM1 3'UTR, miR-36 mimic and miR-36 inhibitor. GLuc activity 
was monitored at 18h, 24h, 36h, 84, and 72h post-transfection and was normalized to SEAP. 
Data is plotted as GLuc/SEAP ratio where the x-axis indicates the transfection and time points, 
and y-axis indicates the relative luciferase activity. The relative expression of IFITM1 and miR-
36 in KSHV-infected BJAB (C) and HMVEC-d (D) cells was monitored by qRT-PCR. The 
expression was measured in terms of cycle threshold value (Ct) and normalized to expression 
of β-actin and snRNA RNU6B, respectively. The x-axis denotes the time point post KSHV 
infection in minutes and y-axis denotes fold change in expression of IFITM1 and miR-36. The 
R2 values for the miRNA expression during the early course of KSHV infection is provided. Bars 
(B-D) represent average ± s.d. of five individual experiments. Student t test was performed to 
compare groups. Two-tailed P value of 0.05 or less was considered statistically significant. 
*p<0.05; **p,0.01; ***p<0.001; NS-not significant. 
 
Figure 5. IFITM1 overexpression enhances KSHV infection of cells. (A) KSHV infection of 
cells induce IFITM1 expression. Western blotting analysis demonstrate KSHV infection of 
target cells to increase IFITM1 protein levels. Expression of IFITM1 levels was normalized to β-
actin protein levels. Data representing the IFITM1 protein expression levels are presented as 
fold increase (average±s.d. from three experiments) in the boxes below the panels. The results 
presented are a representative data and the original full-length blots of the cropped images is 
provided in Supplemental Figure 4. (B) Flow cytometry data confirming the expression of 
IFITM1 protein in transfected cells. BJAB and HMVEC-d cells transiently transfected with 
pQCXIP/IFITM1 vector were analyzed for the expression of IFITM1 protein. This was performed 
by staining untransfected cells (red line) and transfected cells (green line) with rabbit polyclonal 
anti-IFITM1 antibodies followed by incubation with goat anti-rabbit FITC, before examining by 
FACS. As a control for the antibodies, transfected cells stained only with polyclonal anti-IFITM1 
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antibodies (purple dark line) were used. (C-D) IFITM1 enhances KSHV infection of cells. (C) 
BJAB and (D) HMVEC-d cells were untransfected, mock transfected, transiently transfected with 
pQCXIP/IFITM1, pQCXIP, co-transfected with pQCXIP/IFITM1 and miR-36 mimic, or co-
transfected with pQCXIP/IFITM1 and control mimic (miR-NC) prior to infecting with 10 MOI of 
KSHV, EBV or HSV-2. Data was plotted to represent the percentage of virus infection as 
determined by monitoring the change in RNA copy numbers of KSHV-ORF50, EBV-BRLF1 or 
HSV-2 US1, respectively. Bars (C-D) represent average ± s.d. of five individual experiments. 
Student t test was performed to compare the effects of IFITM1 and miR-36 mimic on virus 
infection of cells compared to appropriate control groups. Two-tailed P value of 0.05 or less was 
considered statistically significant. **p,0.01; ***p<0.001; NS-not significant. 
 
Figure 6. Knock-down of IFITM1 by siRNA decreases KSHV, EBV and HSV-2 infection of 
cells. (A) Northern blotting to monitor the effect of transfecting cells with siRNA specific 
to IFITM1. Target cells were untransfected or transfected either with ds siRNA or (NS)siRNA 
controls. After 0, 12, 24, and 48 hours after transfection, total RNAwas isolated from the cells 
and subjected to Northern blotting as per standard protocols to monitor IFITM1and β-actin 
mRNA. Data representing the IFITM1 mRNA expression levels are presented as fold increase 
(average±s.d. from three experiments) in the boxes below the panels. The results presented are 
a representative data and the original full-length blots of the cropped images is provided in 
Supplemental Figure 5. (B) BJAB and HMVEC-d cells were un-transfected, transfected with 
IFITM1-specific siRNA, or NS- siRNA prior to infecting cells with 10 MOI of KSHV. IFITM1 
mRNA levels was monitored at 15min PI by Northern blotting and normalized to β-actin levels. 
(C) KSHV, EBV, and HSV-2 infection significantly lowered in cells silenced for IFITM1 
expression. BJAB and HMVEC-d were either un-transfected, transfected with IFITM1-specific 
siRNA, or transfected with (NS)siRNA before infecting with KSHV, EBV or HSV-2. Data was 
plotted to represent the percentage of virus infection as determined by monitoring the change in 
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RNA copy numbers of KSHV-ORF50, EBV-BRLF1, or HSV-2 US1. Bars represent average ± 
s.d. of five individual experiments. Student t test was performed to compare groups. Two-tailed 
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1. MATERIALS AND METHODS 
Cell culture: BJAB cells were propagated in phenol red–free RPMI medium (Invitrogen, 
Carlsbad, CA) while HFF and 293 cells were cultured in Dulbecco modified Eagle medium 
(DMEM) containing 10% charcoal-stripped fetal bovine serum (FBS; Atlanta Biologicals, 
Lawrenceville, GA), L-glutamine, and antibiotics80. HMVEC-d cells were propagated in EGM 
MV-microvascular endothelial cell medium (Clonetics) as per standard protocols. The passage 
numbers for HFFs and HMVEC-ds used in this study ranged between 6 - 10, and 5 - 9, 
respectively (Akula et al., 2005). 
 
Cytotoxicity assay 
Target cells were treated with different concentrations of miR-36 mimic and inhibitor at 37°C in a 
V-bottom 96-well plate. After a 24h incubation, the cells were analyzed for the expression of 
LDH, as an indicator of cell death. The LDH assay was performed using the CytoTox 96 non-
radioactive kit (Promega) as per earlier studies(Dyson et al., 2010). G418 (Sigma-Aldridge, St. 
Louis, MO) and cytochalasin D (Sigma-Aldridge) were used as known cell death inducers. 
 
Virus infection of cells, RNA extraction, and monitoring virus infection 
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BJAB, HFF, and HMVEC-d cells were infected with 10 multiplicity of infection (MOI)(Hamden et 
al., 2004; Walker et al., 2014) of KSHV, EBV, and HSV-2. The cells were left uninfected or 
infected for 5, 10, 15, and 30min prior to washing the cells twice in PBS and processed 
appropriately for RNA extraction. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, 
CA). The RNA concentration was measured with a NanoDrop ND-2000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA), and then verified for quality using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only the RNA samples with 260/280 
ratios of 1.8 to 2.0 were used in the study. 
 Extracted RNA was used to synthesize cDNA and the expression of ORF50 was 
monitored by qRT-PCR using specific primers as per earlier studies(Dyson et al., 2010). 
Expression of ORF50 was used as a scale to measure KSHV infection of cells. As reported 
earlier(Walker et al., 2014), the lowest limit of detection in the standard samples was 6–60 
copies for the ORF50 gene. The results from the use of ORF50 primers were consistently 
confirmed by monitoring the expression of another viral immediate early (IE) gene, vGPCR 
(data not shown). EBV and HSV-2 infection was monitored using primers to BRLF1 (homolog of 
KSHV ORF50)(Robinson et al., 2011) and HSV-2 IE gene, US1(Kaneko et al., 2008). 
 
Flow cytometry 
Flow cytometry was used to monitor expression of IFITM1 in the cells. Briefly, target cells were 
fixed in 10ml of ice-cold acetone for 20min, washed thrice in PBS prior to incubating cells in 
25µg/ml of rabbit polyclonal antibody to IFITM1 (EMD Millipore, Billerica, MA) for 60min at 4°C. 
The cells were washed thrice in PBS and further incubated with FITC conjugated appropriate 
secondary IgG at 4°C for 30 min, washed and analyzed in a FACScan flow cytometer (Becton 
Dickinson) with appropriate gating parameters. 
 
Real-time qRT-PCR analysis of the expression of miRNAs 
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The quality of RNA was tested using a spectrophotometer. Only the RNA samples with 260/280 
ratios of 1.8 to 2.0 were used in the study. Approximately 500ng of RNA was reverse 
transcribed in a 25µl reaction volume using the All-in-oneTM miRNA qRT-PCR detection kit 
(GeneCopoeia, Rockville, MD). Briefly, the cDNA was synthesized in a 25μl reaction mix 
containing 5μl of 5x reaction buffer, 2.5U/μl Poly A Polymerase, 10ng/μl MS2 RNA, and 1µl 
RTase Mix. The reaction was performed at 37°C for 60 min and terminated at 85°C for 5 min. 
cDNA that was produced in the RT reaction was diluted ten-fold and was used as the template 
for the PCR reaction in an Applied Biosystems ViiA 7 Real-Time PCR System (Life 
Technologies, USA). In this system, MS2 RNA was used as an external reference for the quality 
of the extracted miRNAs, and RNU6B, RNU44, RNU48, and RNU49 were used for 
normalization. The expression levels of miRNAs were measured employing qRT-PCR with the 
SYBR green detection and specific forward primer for the mature miRNA sequence and the 
universal adaptor reverse primer (GeneCopoeia, USA). 
 
Silencing IFITM1 using siRNA 
Expression of IFITM1 was inhibited by the transfection of double-stranded (ds) RNA oligos as 
per standard protocols(Akula et al., 2005). IFITM1 siRNA was purchased from Dharmacon RNA 
Technologies (Lafayette, CO). Briefly, 1 x 106 cells were washed twice in RPMI and incubated in 
phenol red–free RPMI supplemented with 5% FBS at 37°C. After 24 hours incubation 
(considered as 0h for experiments in Fig. 6A), the target cells were transfected with either ds 
short interfering RNAs (siRNAs) or the nonspecific (NS) controls using Fugene HD as per 
manufacturer’s recommendations (Promega). At 0, 12, 24, and 48 hours after transfection, total 
RNA was isolated from the cells and subjected to Northern blotting to monitor the expression of 
IFITM1 and β-actin mRNA as per the protocol mentioned in the “Materials and methods” section 
describing Northern blotting. In another set of experiments, untransfected cells and cells 
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transfected with siRNA or (NS)siRNA for 12h were infected with 10 MOI of KSHV. At the end of 
30min PI, KSHV infection was assessed by monitoring ORF50 expression by qRT-PCR. 
 
2. SUPPLEMENTAL FIGURES: 
Supplemental Figure 1. Secondary structures of Pre-mir-36. Structure was predicted using the 
RNAstructure software and base-pairing probability depicted in colors. miR-36 is located at 3p 
of the duplex (Reuter and Mathews, 2010). 
 
Supplemental Figure 2. RNA hybrid analysis shows the miR-36 binding site located in 3'UTR 
of IFITM1 mRNA. This is predicted using DIANA and MiRmap algorithms (Paraskevopoulou et 
al., 2013; Vejnar and Zdobnov, 2012). 
 
Supplemental Figure 3. Original Western blots of the data presented in Figure 4a. 
 
Supplemental Figure 4. Original Western blots of the data presented in Figure 5a. 
 
Supplemental Figure 5. Original Northern blots of the data presented in Figure 6a, b. 
 
Supplemental Figure 6. Putative target genes for miR-36. miR-36 has been predicted to 
modulate expression of 25 target genes with confirmed roles during early stages of virus 
infection. DIANA and MiRamp tools was used for prediction of miR-36 target genes. 
 
Supplemental Figure 7. IFITM1 and IFITM3 but not IFITM2 enhance KSHV infection of 
cells. BJAB, HMVEC-d, HFF and 293 cells were either untransfected, mock transfected, 
transiently transfected with pQCXIP/IFITM1, pQCXIP/IFITM2, pQCXIP/IFITM3, or pQCXIP prior 
to infecting with 10 MOI of KSHV. Data was plotted to represent the changes in KSHV-ORF50 
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RNA copy numbers at 30min PI. Bars represent average ± s.d. of five individual experiments. 
Student t test was performed to compare groups. Two-tailed P value of 0.05 or less was 
considered statistically significant. *p<0.05; **p,0.01; ***p<0.001; NS-not significant. 
 
Supplemental Figure 8. KSHV infection of cells induce expression of IFNs in target cells. 
Expression of IFNs were detected by qRT-PCR at different time points post-infection in BJAB 
(A) and HMVEC-d (B) cells infected with 10 MOI of KSHV compared to uninfected cells. The 
qRT-PCR data was plotted for fold changes in the expression of IFNs in cells during the course 
of infection when compared to the uninfected cells. Bars represent average ± s.d. of five 
individual experiments. Student t test was performed to compare expression of IFNs in 
uninfected cells versus 15, and 30min PI. Two-tailed P value of 0.05 or less was considered 
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The oncogenic gammaherpesviruses, Epstein–Barr virus (EBV) and Kaposi’s sarcoma 
herpesvirus (KSHV), are etiologically associated with a variety of human cancers, including 
Burkitt’s lymphoma (BL), Hodgkin lymphoma (HL), Kaposi's sarcoma (KS), and primary effusion 
lymphoma (PEL). Recently, we demonstrated KSHV infection of B- and endothelial cells to 
significantly upregulate the expression of interferon induced transmembrane protein 1 (IFITM1) 
which in turn enhances virus entry [Hussein and Akula, 2017]. In this study, we determined EBV 
infection of cells to trigger IFITM1 expression, in vitro. Silencing IFITM1 expression using siRNA 
specifically lowered gammaherpesvirus infection of cells at a post binding stage of entry. A 
natural model system to explore the effect of IFITM1 on gammaherpesvirus infection in vivo is 
infection of BALB/c mice with murine gammaherpesvirus 68 (MHV-68). Priming mice with siRNA 
specific to IFITM1 significantly lowered MHV-68 titers in the lung specimens compared to 
priming with (NS)siRNA or PBS. MHV-68 titers were monitored by plaque assay and qPCR. 
Taken together, for the first time, this study provides insight into the critical role of IFITM1 to 




Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma 
(KS), the most common cancer afflicting HIV-infected individuals (Chang et al., 1994). KSHV is 
also associated with two other B cell lymphoproliferative disorders: primary effusion lymphoma 
(PEL) and multicentric Castlesman disease (MCD) (Hamden et al., 2005). KSHV belongs to the 
-herpesvirinae subfamily (genus Rhadinovirus) and was first described in 1994 (Chang and 
Moore, 2014; Neipel and Fleckenstein, 1999). KSHV is among the list of viral pathogens 
estimated to cause 12-25% of human cancers worldwide (La Ferla et al., 2013; Morrison et al., 
2015). 
 KSHV internalization is a highly orchestrated but complicated event yet to be thoroughly 
understood. The initial step in the virus entry process is the reversible step of binding or 
attachment to the target cells (Akula et al., 2001b). This step is primarily achieved by KSHV 
interacting with the ubiquitously expressed cell surface receptor, heparan sulfate (HS) (Akula et 
al., 2001a; Akula et al., 2001b). The attachment to cells enables KSHV to interact with entry 
promoting receptors allowing the virus to eventually enter the cell (Akula et al., 2002; Hahn et 
al., 2012). In a recent study, we determined that interferon (IFN)-induced transmembrane-1 
(IFITM1) expression to significantly enhance KSHV infection of human B and endothelial cells 
(Hussein and Akula, 2017a). In opposition to this process, over-expression of microRNA 
(miRNA)-36 (miR-36) significantly lowered expression of IFITM1 and thus the virus entry. We 
concluded IFITM1 to play a role in promoting early stages of KSHV infection of cells, in vitro. 
 Over the past few years, several novel genes downstream of type I IFN signaling that 
inhibit infection by individual or multiple families of viruses have been described. There are two 
genetically and functionally distinct families of interferon stimulated genes (ISGs) that have 
antiviral properties, they are IFN-induced proteins with tetratricopeptide repeats (IFIT) and 
IFITMs. IFITs contribute to an antiviral state against some viruses by binding components of the 
eIF3 translation initiation complex and inhibiting protein translation (Guo et al., 2000). In 
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contrast, IFITMs block viral infection at the entry stage (Lu et al., 2011). IFITMs are a double-
edged sword when it comes to influencing viral entry; they can also enhance viral entry 
(Hussein and Akula, 2017a; Warren et al., 2014; Zhao et al., 2014). Interestingly, IFITM1 
expression not only enhanced KSHV infection of cells, but also infection of cells with a closely 
related herpesvirus belonging to the -herpesvirinae subfamily, Epstein-Barr virus (EBV) 
(Hussein and Akula, 2017a). 
 Both KSHV and EBV are the most relevant human -herpesviruses. Therefore, we 
conducted further studies to confirm the role of IFITM1 in KSHV and EBV infections, in vitro and 
in vivo. For in vivo studies, we used murine -herpesvirus 68 (MHV-68), that serves as a good 
model to understand -herpesvirus (KSHV and EBV) pathogenesis (Leang et al., 2011; Steer et 
al., 2010). Herein, we provide pioneering evidence to demonstrate a key role for IFITM1 in the in 
vitro and in vivo infection of -herpesviruses. 
 
MATERIALS AND METHODS 
Cells 
Human Burkitt lymphoma B cell line (BJAB) was used in this study. BJAB cells were propagated 
in phenol red–free RPMI medium (Invitrogen, Carlsbad, CA) containing 10% charcoal-stripped 
fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA), L-glutamine, and antibiotics 
(Akula et al., 2005). The cells used in this study were negative for mycoplasma as tested by 
Mycoplasma PCR ELISA (Roche Life Science, Indianapolis, IN). 
 
Virus and mice 
The viruses used in this study were wild-type KSHV (Dyson et al., 2010), EBV (Bentz et al., 
2010), and MHV-68 (Ancicova et al., 2015). Female 6-week-old inbred BALB/c mice supplied by 
the Faculty of Veterinary Medicine, Brno, Czech Republic were used in this study. 
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Virus infection of cells, RNA and DNA extraction, and monitoring virus infection 
BJAB cells were infected with 10 multiplicity of infection (MOI) of KSHV and EBV. The cells 
were left uninfected or infected for 5, 10, 15, and 30min prior to washing the cells twice in PBS 
and processed appropriately for RNA and DNA extraction. Total RNA was extracted using 
TRIzol (Invitrogen, Carlsbad, CA). The RNA concentration was measured with a NanoDrop ND-
2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA), and then verified for quality 
using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only the RNA 
samples with 260/280 ratios of 1.8 to 2.0 were used in the study. Viral DNA was extracted by 
isolating total genomic DNA and determining the internalized virus particles by qPCR (Walker et 
al., 2016). 
 Extracted RNA was used to synthesize cDNA and the expression of ORF50 was 
monitored by qRT-PCR using specific primers as per earlier studies (Dyson et al., 2010). 
Expression of ORF50 was used as a scale to measure KSHV infection of cells. As reported 
earlier (Walker et al., 2014), the lowest limit of detection in the standard samples was 6–60 
copies of the ORF50 gene. The results from the use of ORF50 primers were consistently 
confirmed by monitoring the expression of another viral immediate early (IE) gene, vGPCR 
(data not shown). EBV infection was monitored using specific primers to BRLF1 (homolog of 
KSHV ORF50) (Robinson et al., 2011).  
 
Transfection of cDNA 
Target cells were transiently transfected with plasmid DNA using FuGene HD (Promega, 
Madison, WI) as per manufacturer’s recommendations. The plasmid, pQCXIP encoding IFITM1, 
used in this study was kindly gifted to us by Dr. Michael Farzan (The Scripps Research Institute, 
Jupiter, USA). FuGene HD/DNA ratios of 3:1 for adherent cell lines and 6:1 for suspension cell 
lines were used. These were transient transfections and experiments using these cells were 
conducted 48h post transfection. 
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In vitro silencing IFITM1 using siRNA 
Expression of IFITM1 was inhibited by the transfection of double-stranded (ds) RNA oligos as 
per standard protocols (Hussein and Akula, 2017a). IFITM1 siRNA was purchased from 
Dharmacon RNA Technologies (Lafayette, CO). Briefly, untransfected cells and cells 
transfected with siRNA or (NS)siRNA for 12h were infected with 10 MOI of KSHV. At the end of 
30min PI, KSHV infection was assessed by monitoring ORF50 expression by qRT-PCR. 
 
Binding assay 
The effect of IFITM1 on KSHV binding to target cells was assessed by PCR detecting the cell-
bound KSHV DNA. Briefly, untransfected cells or cells transfected with (NS)siRNA, or siRNA 
specific to IFITM1 were infected with 10MOI of KSHV at +4C. After 60min of incubation with 
virus, cells were washed three times with PBS to remove the unbound virus. Cells were 
pelleted, and total DNA including those representing the cell bound KSHV was isolated using 
DNeasy kit (Qiagen, Valencia, CA) and subjected to qPCR analysis monitoring ORF50 
according to recently published work (Walker et al., 2014). Incubating KSHV with 100µg/ml of 
heparin and chondroitin sulfate A (CSA; Sigma-Aldridge) for 1h at 37C were used as known 
positive and negative controls. 
 
Animal studies 
Animal studies using BALB/c mice was performed to understand the effects of IFITM1 on -
herpesviruses, in vivo. Briefly, five groups of mice (n=5/group) used in this study were (i) virus 
free or uninfected; (ii) MHV-68 infected; (iii) IFITM1 siRNA primed + MHV-68 infected; (iv) 
(NS)siRNA primed + MHV-68 infected; and (v) PBS primed + MHV-68 infected. The 
experimental design is detailed in the schematic (Fig. 1). Mice were primed with PBS, 
20µg/mouse of IFITM1-siRNA, or (NS)siRNA on day 0 by tail vein injection. The uninfected and 
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the MHV-68 infected groups were left untreated. On day 02, only groups (iii), (iv), and (v) were 
tail vein-injected with IFITM1 siRNA, (NS)siRNA, and PBS, respectively. After this step, animals 
in groups (ii), (iii), (iv), and (v) were intranasally (i.n) infected with 2 x 104 PFU (20µl) of MHV-68. 
On day 04, the animals in groups (iii), (iv), and (v) received tail vein injections of IFITM1 siRNA, 
(NS)siRNA, and PBS, respectively; while animals in groups (i) and (ii) were left undisturbed. On 
day 06, mice were sacrificed and lungs were collected. Relative IFITM1 gene expression was 
calculated using the  method (Schmittgen and Livak, 2008), using β-actin mRNA 
expression as reference gene and the virus free group as the calibrator. Plaque assay 
(Stiglincova et al., 2011) and qPCR (Hajnicka et al., 2017) was conducted to determine MHV-68 
infection of lungs.  
All animal experiments were performed according to the European Union standards, and 
fundamental ethical principles including animal welfare requirements were respected. All 
experiments were done with the approval of State Veterinary and Food Administration of the 
Slovak Republic (2937/10221). 
 
RESULTS 
Infection of BJAB cells with -herpesviruses induce expression of IFITM1. 
In a recently concluded study, we demonstrated the ability of KSHV to induce IFITM1 
expression during early stages of infection (Hussein and Akula, 2017a). In the present study, we 
analyzed the effect of another closely related -herpesvirus, EBV, on IFITM1 expression. IFITM1 
transcript (Fig. 2A) and protein expression (Fig. 2B) levels were significantly elevated with EBV 
and KSHV infection of BJAB cells. The expression of IFITM1 increased in virus infected cells as 
early as 5min PI which was elevated by 10min and 15min PI in BJAB, but significantly declined 




IFITM1 expression is a necessity for -herpesvirus infection of cells. 
In a recently concluded study, we demonstrated a crucial role for IFITM1 expression in KSHV 
infection of cells. This was possible by monitoring the expression of ORF50 transcript as a 
measure of infection. In the current study, we analyzed internalization of the -herpesviruses by 
monitoring the internalized viral DNA compared to the expression of ORF50 and BRLF-1 
transcripts. BJAB cells (Fig. 3A) expressing IFITM1 supported a significantly enhanced KSHV 
infection compared to those cells that were left untransfected, mock transfected, or transfected 
with the empty vector. To authenticate the role for IFITM1 in enhancing infection of -
herpesviruses, we tested the effect of silencing IFITM1 on the internalization of the viruses. 
Briefly, we first transfected cells with siRNA specific for IFITM1. Northern blotting was performed 
at 0, 12, 24, and 48 hours after transfection as per the standard protocols to monitor IFITM1 
mRNA expression. A maximum IFITM1 mRNA inhibition was observed in cells transfected with 
siRNA specific to IFITM1 at 12h post transfection (Hussein and Akula, 2017a). On the same 
lines, internalized -herpesviruses in cells silenced for the expression of IFITM1 was significantly 
lower compared to cells that were untransfected or transfected with (NS)siRNA (Fig. 3B). The 
expression of viral transcripts BRLF-1 and ORF50 for EBV and KSHV, respectively, was also 
decreased in cells transfected with siRNA specific to IFITM1 compared to (NS)siRNA. Taken 
together, the results clearly implicate a role for IFITM1 in enhancing KSHV, and EBV infection of 
cells. 
 
IFITM1 enhances virus infection at a post-attachment stage. 
To enumerate the role of IFITM1 on binding of viruses to target cells, we used untransfected or 
BJAB cells transfected with siRNA to IFITM1, or (NS)siRNA. These cells were used in binding 
assays. The binding assay performed on BJAB cells demonstrated that the transfection of cells 
with (NS)siRNA or siRNA specific to IFITM1 did not block KSHV and EBV from binding the 
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target cells (Fig. 4A). Incubating KSHV with heparin but not CSA significantly blocked KSHV 
and EBV from binding cells (Fig. 4A). This data was confirmed by electron microscopy by 
monitoring KSHV (Fig. 4B) and EBV (data not shown) binding to BJAB cells. Based on these 
results, we concluded IFITM1 to alter virus infection at a post-attachment stage of entry. 
 
Silencing IFITM1 expression in BALB/c mice lowered MHV-68 infection. 
MHV-68 is regarded as a substitute for human -herpesvirus and has been widely used in in 
vivo studies [46, 72, 77]. We used mouse siRNA specific to IFITM1 to appreciate the effect of 
IFITM1 on MHV-68 infection, in vivo, using BALB/c mice. Priming mice with siRNA specific to 
IFITM1 significantly lowered expression of IFITM1 in the lungs of the mice compared to 
(NS)siRNA (Fig. 5A). Our data demonstrates a significant increase in the leukocyte count in 
mice that were infected with MHV-68 compared to the uninfected mice (Table 1). The leukocyte 
count in infected mice that were primed with siRNA specific to IFITM1 was significantly lower 
compared to those that were primed with PBS or (NS)siRNA. We did not notice atypical 
lymphoid monocytes in these animals. 
 MHV-68 infection of mice was monitored by the traditional plaque assay. Plaque assay 
could detect MHV-68 in lungs of the infected mice (Fig. 5B). MHV-68 infection was significantly 
inhibited in the mice that were primed with siRNA specific to IFITM1 compared to those that 
were primed with (NS)siRNA or PBS (Fig. 5B). The results were confirmed by performing qRT-
PCR (Fig. 5C). Taken together, silencing the expression of IFITM1 significantly hampered MHV-
68 infection of mice. 
 
DISCUSSION 
Many different types of cellular sensors can detect viruses and induce the expression of the 
type I interferons (IFNs)—IFN-α and IFN-β. Type I IFNs bind to the ubiquitously expressed 
IFNAR (IFN-α/β receptor), activating the JAK/STAT pathway (Donlin et al., 2014; Ivashkiv and 
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Donlin, 2014). The type I IFN response can induce the expression of hundreds of interferon 
stimulated genes (ISGs) which primarily serve to limit further virus spread and infection 
(Schneider et al., 2014). IFITMs are a family of proteins that have gained popularity as novel 
antiviral ISGs (Weidner et al., 2010). IFITMs are a member of the interferon-induced 125–133 
aa protein family including IFITM1, IFITM2, IFITM3, IFITM5 and IFITM10. This family of proteins 
is located on chromosome 11 of the human genome and originally described as highly inducible 
genes by α- and γ-interferons (IFNs) (Friedman et al., 1984; Hickford et al., 2012; Reid et al., 
1989). IFITM proteins are significantly upregulated by type I and II IFNs and are critical for anti-
viral innate immune responses (Brass et al., 2009; Deblandre et al., 1995; Evans et al., 1990; 
Smith et al., 2006). Recent reports indicate IFITMs play a significant role in virus entry. IFITMs 
inhibits entry of many RNA viruses including influenza A H1N1 Virus, West Nile Virus, Dengue 
Virus, HIV, and HCV (Brass et al., 2009; Narayana et al., 2015; Yu et al., 2015a). However, 
IFITMs can also enhance viral infection of cells: (i) both IFITM1 and IFITM3 modestly enhance 
human papillomavirus 16 (HPV-16) infection of a variety of cells (Warren et al., 2014); (ii) Zhao 
et al have shown type I IFN-α, IFN-γ, and type II IFN-λ to significantly promote infection of 
human coronavirus, HCoV-OC43 by the induction of IFITM proteins. The authors reported that 
the over-expression of IFITM3 significantly increased susceptibility of Huh7.5 cells to HCoV-
OC43 infection (Zhao et al., 2014); and (iii) Inhibition of IFITM1 expression by specific miR-36 
mimic significantly inhibited early stages of KSHV infection of human B and endothelial cells 
(Hussein and Akula, 2017a). In general, the IFITM family of proteins affects virus entry of cells. 
 In the current study, we demonstrated that EBV, another -herpesvirus, induces IFITM1 
expression during the early stages of infection and it followed an identical pattern as that of 
KSHV (Fig. 2). We went one step further in demonstrating that either over-expressing or 
silencing the expression of IFITM1 significantly alter not only the internalization of the -
herpesviruses (Fig. 3A) but also the ability to establish infection as monitored by the expression 
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of the respective viral transcripts (Fig. 3B). IFITM1 promotes -herpesvirus infections at a post-
binding stage of entry as silencing IFITM1 did not alter the KSHV and EBV binding to the cell 
surfaces (Fig. 4). 
A natural model system to investigate -herpesvirus-host interactions is the infection of 
mice with MHV-68, a natural pathogen of wild rodents (Barton et al., 2011; Cipkova-Jarcuskova 
et al., 2013). Therefore, to understand the in vivo effects of IFITM1 on -herpesviruses, we used 
MHV-68 as a model virus. Leukocyte counts were increased in response to MHV-68 infection of 
mice (Table 1). This increase in the leukocyte count was significantly lowered when the mice 
were primed with siRNA compared to (NS)siRNA and PBS. We did not observe atypical 
lymphoid monocytes in the mice from all the groups used as it was too early to observe any 
such changes. Priming mice with siRNA specific to IFITM1 significantly lowered expression of 
IFITM1 in lungs compared to PBS, (NS)siRNA (Fig. 5A). It was determined by plaque assay 
and qPCR that a decrease in the expression of IFITM1 resulted in a significant decrease in 
MHV-68 infection of lungs obtained from the mice (Fig. 5B, C). This study focused primarily in 
monitoring infection of lungs because intranasal MHV-68 infection of mice results in acute lytic 
infection of lungs followed by the establishment of lifelong latency (Flano et al., 2000). Taken 
together, we demonstrate for the first time a crucial role for IFITM1 in the in vivo infection of -
herpesviruses. 
The results from this study puts forth crucial questions in terms of better understanding 
the role of IFITM1 in altering entry of -herpesviruses. Numerous mechanisms by which IFITM 
proteins alter virus entry have been proposed and it is not limited to the following: (i) acting as 
pattern recognition receptors by sensing virus infection and activation of downstream cellular 
signaling pathways (Brass et al., 2009); and (ii) reducing membrane fluidity and curvature, and 
by possibly disrupting intracellular cholesterol homeostasis (Amini-Bavil-Olyaee et al., 2013; Li 
et al., 2013a). Albeit, none of the mechanisms have been confirmed. Future studies will be 
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aimed at delineating that eluding mechanism by which IFITM1 enhance the internalization of the 
-herpesviruses. These studies are crucial because they help us understand the role of ISGs in 
modulating -herpesvirus infection of cells. In addition, the results from this study will benefit in 
designing IFITM1 targeted therapies to treat cancers (Borg et al., 2016; Lui et al., 2017), and -
herpesvirus infections including that of HIV (Raposo et al., 2017) and HCV (Wilkins et al., 2013). 
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Figure 1. Schematic depicting the animal study design. The study was approved by the 
State Veterinary and Food Administration of the Slovak Republic (2937/10221) and strictly 
followed the European Union standards. 
 
Figure 2. Infection of BJAB cells with EBV and KSHV induce expression of IFITM1. (A) 
The relative expression of IFITM1 in EBV or KSHV infected BJAB cell was monitored by qRT-
PCR. The expression was measured in terms of cycle threshold value (Ct) and normalized to 
expression of β-actin. The x-axis denotes the time point post virus infection in minutes and the 
y-axis denotes fold change in expression of IFITM1. (B) Western blotting analysis demonstrates 
EBV or KSHV infection of BJAB cells to increase IFITM1 protein levels. Expression of IFITM1 
levels was normalized to β-actin protein levels. Data representing the IFITM1 protein expression 
levels are presented as fold increase (average ± s.d. from three experiments) in the boxes 
below the panels. Bars (A) represent average ± s.d. of five individual experiments. Columns 
with different alphabets indicate the values to be statistically significant (p < 0.05) by least 
significance difference (LSD). 
 
Figure 3. IFITM1 expression is a necessity for EBV and KSHV infection of cells. (A) 
Overexpression of IFITM1 enhances EBV and KSHV infection of cells. BJAB cells were 
untransfected, mock transfected, transiently transfected with pQCXIP/IFITM1, or pQCXIP prior 
to infecting with 10 MOI of EBV or KSHV. (B) Silencing the expression of IFITM1 by siRNA 
significantly decreased EBV and KSHV infection of cells. BJAB cells were either un-transfected, 
transfected with IFITM1-specific siRNA, or transfected with non-specific (NS) siRNA before 
infecting with KSHV, or EBV. Data was plotted (A, B) to represent the percentage of virus 
infection as determined by monitoring the change in copy numbers of viral DNA or RNA copy 
numbers of BRLF1 and ORF50 of EBV and KSHV respectively. Bars represent average ± s.d. 
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of five individual experiments. Columns with different alphabets indicate the values to be 
statistically significant (p < 0.05) by LSD. 
 
Figure 4. IFITM1 enhancement of EBV and KSHV infection of cells is at a post-attachment 
stage of virus entry. (A) EBV and KSHV binding to BJAB cells were monitored in cells that 
were untransfected, untransfected and treated with heparin or CSA, or transiently transfected 
with IFITM1-specific siRNA, or transfected with non-specific (NS) siRNA. Data was plotted to 
represent the percentage of EBV or KSHV binding to BJAB cells treated differently compared to 
the untransfected cells. (B) Representative electron micrographs of KSHV binding to BJAB cells 
is depicted. KSHV allowed to bind at 4°C to BJAB cells that were untransfected, or transiently 
transfected with IFITM1-specific siRNA, or (NS) siRNA. After 60min cells were fixed with 2% 
glutaraldehyde. Thin sections were examined by transmission electron microscopy. Enveloped 
virus particles bound to the BJAB cells surfaces are indicated by the arrows. Magnification: 
82,000X (solid bar denotes 500nm). Bars (A) represent average ± s.d. of five individual 
experiments. Columns with different alphabets indicate the values to be statistically significant 
(p < 0.05) by LSD. 
 
Figure 5. Silencing IFITM1 expression in BALB/c mice lowered MHV-68 infection. The four 
groups of mice (n=5/group) that were used in this study are as follows: (i) uninfected; (ii) MHV-
68 infected; (iii) IFITM1 siRNA primed + MHV-68 infected; (iv) (NS)siRNA primed + MHV-68 
infected; and (v) PBS primed + MHV-68 infected. On 7dPI, expression of (A) IFITM1 or (B, C) 
virus titer by (B) plaque assay and (C) qPCR was determined. (B) Replication of the MHV-68 in 
the lungs of the Balb/c mice (n=5) was determined by plaque assay on Vero cells. The data 
represent the mean ± SD of three independent experiments, each performed in duplicates. The 
results are expressed as relative ratios of plaque numbers in MHV-68 infected mice primed with 
siRNA, (NS)siRNA, or PBS treated groups to that in the MHV-68 infected group (virus control, 
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100%). Bars (A, B, and C) represent average ± s.d. of five mice. Columns with different 


















Groups (n=7) Number of leukocytes per 1 µl of blood 
Uninfected 11633 ± 1500 
MHV-68 14480 ± 1943 
siRNA + MHV-68 11031 ± 2179 
(NS)siRNA + MHV-68 14520 ± 2431 

















Arrival of animals: procure 6 week old BALB/c mice (n=5/group)
Day 6 (96h post MHV-68 infection):  sacrifice animals and collect the different organs*.  Infection will be monitored by performing plaque assay¥ and PCR€. 
The efficiency of siRNA will be assessed by monitoring IFITM1 expression by RT-PCR.
*Organ collected: lungs. Groups of mice:
(i) Uninfected
(ii) MHV-68
(iii) siRNA + MHV-68
(iv) (NS)siRNA + MHV-68
(v) PBS + MHV-68
Day 4 (siRNA): tail vein injection of mice with siRNA, or (NS)siRNA @ 20µg/mouse.
Day 2 (siRNA + MHV-68):  tail vein injection of mice with siRNA, or (NS)siRNA @ 20µg/mouse
+
intranasally (i.n.) administration of MHV-68 at a dose of 2 x 104 PFU (20 µl)
Day 0 (siRNA):  tail vein injection of mice with siRNA, or (NS)siRNA @ 20µg/mouse.
Control groups will include mice that are left untreated and those that receive an equal volume of PBS (vehicle control).
DESIGN to study the role of IFITM1 on MHV-68 infection of mice






































































































SUMMARY AND FUTURE DIRECTIONS 
 
Cellular and KSHV-encoded miRNAs have been demonstrated to regulate KSHV infection in 
terms of latency, reactivation, virus replication, and tumor formation. To date, little is known 
about the role of miRNAs in regulating early stages of virus infection. Our studies, for the first 
time, demonstrate the ability of KSHV to significantly alter the expression of cellular miRNAs 
during the initial stages of infection. Several of these miRNAs in turn target cellular genes to 
inhibit virus entry (Summary Figure). 
In the first study (Chapter 2), we used deep sequencing to identify and examine the host 
cell miRNAs expressed by a human B cell line (BJAB) in response to KSHV infection that may 
regulate virus internalization and immune response. Small-RNA sequencing data demonstrated 
the significantly altered cellular miRNA expression pattern in response to KSHV infection during 
the first 15 minutes PI. We identified a total of 32 known and 28 novel cellular miRNAs to be 
differentially expressed in KSHV-infected compared to uninfected BJAB cells. These miRNAs 
were further authenticated by qRT-PCR using miRNA-specific primers. 
We also tested the ability of UV-inactivated KSHV (UV-KSHV) to alter the expression of 
cellular miRNAs. Interestingly, profiling of miRNAs expression during the early stages of UV-
KSHV infection of BJAB cells yielded comparable levels as the live wild-type KSHV. These data 
may indicate that the induction of cellular miRNAs by KSHV infection in BJAB cells is purely 
dependent on the interactions between the virus envelope-associated proteins and cell-surface 
receptors, and not due to virus replication. 
miRNA-target prediction analysis indicated that target genes regulated by KSHV-induced 
known miRNAs are mainly involved in regulating cell signaling, initiating transcription of KSHV 
IE genes, promoting virus latency, and modulating the host immune responses. Similarly, novel 
cellular miRNAs that were up-regulated by KSHV infection in our study primarily target genes 
that are involved in virus uptake and immune responses. Using qRT-PCR and Western blotting, 
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we were able to further authenticate some of the target genes that have been shown to be 
regulated by novel miRNAs. These findings provide clear evidence that KSHV entry induces 
cellular miRNAs that in turn regulate virus infection and cellular-antiviral defense mechanisms. 
One of the KSHV-induced miRNAs, miR-36 was shown to be significantly upregulated 
by 15min PI. Thus, our next study (Chapter 3) was to further investigate the role of miR-36 
during virus entry. Initially, we monitored the expression of miR-36 at 5, 10, 15, and 30min PI in 
BJAB and endothelial (HMVEC-d) cells, both are physiologically relevant cells to KSHV biology. 
Our results showed that miR-36 triggered by KSHV at as early as 5 min PI and peaked at 30 
min PI. Transfection of cells with miR-36 mimic significantly inhibited KSHV infection, while miR-
36 specific inhibitor reversed the effects of miR-36 on virus infection of cells. Interestingly, we 
observed similar effects of miR-36 mimic and inhibitor on EBV and HSV-2 infection of cells.  
Using bioinformatics tools, we identified IFITM1 to be one of the most promising targets 
for miR-36. Luciferase assay demonstrated the ability of miR-36 mimic to physically interact with 
IFITM1. Hence, we set out to test the function of IFITM1 during the initial stages of KSHV 
infection. We monitored the expression of IFITM1 at 5, 10, 15, 30 and 60min post-KSHV 
infection of BJAB and HMVEC-d cell lines. There was an inverse correlation observed between 
the expression of KSHV-induced IFITM1 and miR-36. This confirms the direct association 
between virus-induced IFITM1 and endogenous miR-36 expression during KSHV infection. 
Overexpression of IFITM1 in BJAB and HMVEC-d cells significantly enhanced KSHV infection, 
while knock-down of IFITM1 expression by specific siRNA had the opposite effects. We 
observed identical effects of IFITM1 on EBV and HSV-2 infection of cells. These findings 
indicate cellular miR-36 to regulate the internalization of KSHV, EBV, and HSV-2 by targeting 
expression of IFITM1 (Summary Figure). 
Both KSHV and EBV are the most closely related human -herpesviruses. Therefore, we 
analyzed the effect of EBV infection on IFITM1 expression (Chapter 4). Similar to KSHV, 
IFITM1 expression was significantly elevated in BJAB cells infected with EBV. IFITM1 enhances 
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EBV infection at the post-attachment stage as IFITM1-specific siRNA significantly inhibits virus 
infection but has no effect on binding of KSHV and EBV to BJAB cells.  
Finally, we conducted in vivo studies to confirm the role of IFITM1 in KSHV and EBV 
infections (Chapter 4). We used murine -herpesvirus 68 (MHV-68), that is commonly used as a 
model to study -herpesvirus (KSHV and EBV) pathogenesis.  Silencing IFITM1 expression in 
BALB/c mice using IFITM1-specific in vivo siRNA lowered MHV-68 infection. Plaque assay and 
qPCR indicated a sharp decline in the MHV-68 titers in the lung tissues collected from mice that 
were primed with siRNA specific to IFITM1 compared to those that were primed with (NS)siRNA 
or PBS. 
Taken together, our results indicate the following: (i) Interactions between KSHV 
envelope proteins and the host cell receptors trigger the induction of cellular miRNAs; (ii) 
IFITM1 promotes infection of KSHV, EBV, and HSV2; (iii) miR-36 inhibits in vitro KSHV, EBV, 
and HSV2 infection via targeting IFITM1; and (iv) silencing expression of IFITM1 significantly 
decrease -herpesvirus infection of BALB/c mice (Summary Figure). Inhibition of virus entry by 
cellular miR-36 could be a mechanism of superinfection resistance (SIR) (Nethe et al., 2005) 
developed by cells towards KSHV and other related viral pathogens. This idea of a miRNA 
expressed during early stages of infection to actively suppress superinfection is particularly 
appealing because such a mechanism would help to keep a permanent check in the low 
number (1-3%) of KSHV infected cells to undrgoing lytic replication, in vivo. 
 
Our future studies will be dedicated to answering the following questions: 
(i)   What is the molecular mechanism by which KSHV induces cellular miR-36? 
(ii)  How does IFITM1 enhance virus infection?  
(iii) What is the role of host cell receptors in the IFITM1-facilitated virus entry? 






Summary Figure: KSHV-induced miR-36 inhibits KSHV entry by targeting IFITM1. KSHV-
interactions with host cell surface molecules trigger the expression of IFITM1 which in turn 
enhances virus entry. Infected cell responds to IFITM1 expression by upregulation of miR-36 
that inhibits the expression of IFITM1 and blocks KSHV entry. A summary of the events from the 
time of virus binding to the internalization is depicted in a sequentially numbered manner. Green 
lines indicate events that promote virus entry while the red lines denote those events that block 
the virus entry. Future studies are indicated by dotted lines. 
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